Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition) - Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    August 2022

  • Pages
    1180

  • View Count
    57583

Example Insights

Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Context-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Immunotherapies-Market-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-CAR-T-Cell-Therapies-thumb
Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-TCR-based-Therapies-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-TIL-based-Therapies-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Market-Landscape-thumb
Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Key-Opinion-Leaders-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-CAR-T-Construct-Analysis-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Clinical-Trial-Analysis-thumb
Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-T-Cell-Immunotherapies-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-List-of-Cell-Therapy-Manufacturers-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Collaborations-thumb
Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Funding-and-Investments-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Patent-Analysis-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Distributon-by-Indications-thumb
Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Distribution-by-Geography-thumb Global-T-Cell-CAR-T-TCR-and-TIL-Therapy-Market-Promotional-Strategies-thumb  

Overview

Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T therapies, TCR therapies and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Overall, this highly specific and promising form of T-cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. A number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK® (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA.

Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,800 patents related to CAR-T therapies, TCR therapies and TIL therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, close to 440 collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline candidates. Moreover, to fund product development initiatives in this domain, capital investments worth USD 30 billion have been made by various private and public sector investors in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T-cell immunotherapy market is anticipated to witness substantial growth in the mid to long-term.

Scope of the Report

The “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition) - Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2022-2035” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
  • An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
  • A detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TIL, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
  • Elaborate profiles of marketed and mid- to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • An analysis of various type of partnership that have been inked between several stakeholders in the domain of T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary T-cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • An in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, featuring information on current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
  • Elaborate profiles of the several leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several relevant parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America, Europe, Asia Pacific, Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Tim Oldham (Former Chief Executive Officer, Cell Therapies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Peter Ho (Former Director, Process Development, Iovance Biotherapeutics)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to T-cell immunotherapies (specifically CAR-Ts, TCRs and TILs)?
  • What kind of clinical conditions can be treated using T-cell immunotherapies?
  • Who are the leading industry and non-industry players in this market?
  • In which geographies extensive research on T-cell immunotherapy is being conducted?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in T-cell immunotherapy domain? 
  • Who are the key opinion leaders / experts from renowned academic and research institutes who can help drive product development efforts in this domain?
  • How is the intellectual property landscape for global T-cell therapies likely to evolve in the foreseen future?
  • Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture T-cell therapies?
  • What are the key factors that are likely to influence the evolution of the T-cell immunotherapies market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the key promotional strategies used by companies having marketed products?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.

Chapter 4 includes detailed assessment of the current market landscape of more than 970 CAR-T cell therapies that are currently approved or are in different stages of the development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific). 

Chapter 5 includes detailed assessment of the current market landscape of more than 190 TCR-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma,  cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome and nasopharyngeal carcinoma), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso and HLA), source of T-cells (autologous and allogeneic), route of administration (intravenous and intratumoral), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TCR-based therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific). 

Chapter 6 includes detailed assessment of current market landscape of more than 75 TIL-based therapies that are currently in different stages of development. Additionally, it features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (phase III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic areas (oncological disorders, non-oncological disorders), key target indications (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer and squamous cell carcinoma), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dose frequency (single dose and multiple doses), patient segment (children, adults, and seniors), and type of therapy (monotherapy and combination therapy). Further, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TIL-based therapies. The chapter also features an analyses on the developers landscape based on some relevant parameters, including year of establishment, company size (in terms of number of employees), and location of headquarters (North America, Europe and Asia-Pacific). 

Chapter 7 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

Chapter 8 presents a detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TILs, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

Chapter 9 presents an analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Chapter 10 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 11 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 12 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 13 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 14 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 15 provides details on the various investments and grants that have been awarded to several stakeholders focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 16 provides an in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 

Chapter 17 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 18 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. Additionally, it includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 19 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 20 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for T-cell products that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).

Chapter 21 highlights the key promotional strategies that are being implemented by the developers of the approved CAR-T Cell therapies (Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™) and TCR-based therapies (Kimmtrak®). The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 22 includes brief company profiles of the leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 24 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Former Chief Executive Officer, Cell Therapies), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics, Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Former Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 26 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods

3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.7. Challenges Associated with Use of CAR-T Cell Therapies

3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. Development History
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR Therapy
3.8.4. Comparison of CAR-T and TCR-based Therapies

3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. Development History
3.9.2. Development of TILs Therapy

3.10. Key Benefits and Roadblocks
3.11. Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indications
4.2.6. Analysis by Key Target Antigens
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies

4.3. CAR-T Cell Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. TCR-BASED THERAPIES: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Phase of Development and Therapeutic Area
5.2.5. Analysis by Key Target Indication
5.2.6. Analysis by Key Target Antigen
5.2.7. Analysis by Source of T-Cells
5.2.8. Analysis by Route of Administration
5.2.9. Analysis by Phase of Development and Route of Administration
5.2.10. Analysis by Dosing Frequency
5.2.11. Analysis by Target Patient Segment
5.2.12. Analysis by Type of Therapy
5.2.13. Analysis by Phase of Development and Type of Therapy
5.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
5.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies

5.3. TCR-based Therapies: Overall Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters

6. TIL-BASED THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. TIL-based Therapies: Overall Market Landscape
6.2.1. Analysis by Type of Developer
6.2.2. Analysis by Phase of Development
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Key Target Indication
6.2.5. Analysis by Source of T-Cells
6.2.6. Analysis by Route of Administration
6.2.7. Analysis by Dosing Frequency
6.2.8. Analysis by Target Patient Segment
6.2.9. Analysis by Type of Therapy
6.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
6.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies

6.3. TIL-based Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS
7.1. Chapter Overview
7.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigen
7.2.1. Popular Targets Related to Hematological Malignancies
7.2.2. Popular Targets Related to Solid Tumors

7.3. T-Cell Immunotherapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.3.3. Analysis by Trial Status
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Trial Phase
8.3.6. Analysis by Trial Phase and Enrolled Patient Population
8.3.7. Analysis by Target Patient Segment
8.3.8. Analysis by Type of Sponsor / Collaborator
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.3.13. Analysis of Clinical Trials by Geography
8.3.14. Analysis of Enrolled Patient Population by Geography

8.4. TCR-based Therapies: Clinical Trial Analysis
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.4.3. Analysis by Trial Status
8.4.4. Analysis by Trial Registration Year and Trial Status
8.4.5. Analysis by Trial Phase
8.4.6. Analysis by Trial Phase and Enrolled Patient Population
8.4.7. Analysis by Target Patient Segment
8.4.8. Analysis by Type of Sponsor / Collaborator
8.4.9. Analysis by Study Design
8.4.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.4.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.4.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.4.13. Analysis of Clinical Trials by Geography
8.4.14. Analysis of Enrolled Patient Population by Geography

8.5. TIL-based Therapies: Clinical Trial Analysis
8.5.1. Analysis by Trial Registration Year
8.5.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.5.3. Analysis by Trial Status
8.5.4. Analysis by Trial Registration Year and Trial Status
8.5.5. Analysis by Trial Phase
8.5.6. Analysis by Trial Phase and Enrolled Patient Population
8.5.7. Analysis by Target Patient Segment
8.5.8. Analysis by Type of Sponsor / Collaborator
8.5.9. Analysis by Study Design
8.5.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.5.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.5.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.5.13. Analysis of Clinical Trials by Geography
8.5.14. Analysis of Enrolled Patient Population by Geography

9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Qualification
9.4.4. Analysis by Geographical Location of KOLs
9.4.5. KOL Activeness versus KOL Strength
9.4.6. Most Prominent KOLs: Analysis by RA score
9.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9.5. TCR-based Therapies: Key Opinion Leaders
9.5.1. Analysis by Type of Organization
9.5.2. Analysis by Affiliated Organization
9.5.3. Analysis by Qualification
9.5.4. Analysis by Geographical Location of KOLs
9.5.5. KOL Activeness versus KOL Strength
9.5.6. Most Prominent KOLs: Analysis by RA score
9.5.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9.6. TIL-based Therapies: Key Opinion Leaders
9.6.1. Analysis by Type of Organization
9.6.2. Analysis by Affiliated Organization
9.6.3. Analysis by Qualification
9.6.4. Analysis by Geographical Location of KOLs
9.6.5. KOL Activeness versus KOL Strength
9.6.6. Most Prominent KOLs: Analysis by RA score
9.6.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. CAR-T CELL THERAPY PROFILES
10.1. Chapter Overview
10.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
10.2.1. Therapy Overview
10.2.2. Clinical Trial Information
10.2.3. Clinical Trial Endpoints
10.2.4. Clinical Trial Results
10.2.5. Estimated Sales Revenues

10.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
10.3.1. Therapy Overview
10.3.2. Clinical Trial Information
10.3.3. Clinical Trial Endpoints
10.3.4. Clinical Trial Results
10.3.5. Estimated Sales Revenues

10.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
10.4.1. Therapy Overview
10.4.2. Clinical Trial Information
10.4.3. Clinical Trial Endpoints
10.4.4. Clinical Trial Results
10.4.5. Estimated Sales Revenues

10.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
10.5.1. Therapy Overview
10.5.2. Clinical Trial Information
10.5.3. Clinical Trial Endpoints
10.5.4. Clinical Trial Results
10.5.5. Estimated Sales Revenues

10.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
10.6.1. Therapy Overview
10.6.2. Clinical Trial Information
10.6.3. Clinical Trial Endpoints
10.6.4. Clinical Trial Results
10.6.5. Estimated Sales Revenues

10.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
10.7.1. Therapy Overview
10.7.2. Clinical Trial Information
10.7.3. Clinical Trial Endpoints
10.7.4. Clinical Trial Results
10.7.5. Estimated Sales Revenues

10.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
10.8.1. Therapy Overview
10.8.2. Clinical Trial Information
10.8.3. Clinical Trial Endpoints
10.8.4. Clinical Trial Results
10.8.5. Estimated Sales Revenues

10.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
10.9.1. Therapy Overview
10.9.2. Clinical Trial Information
10.9.3. Clinical Trial Endpoints
10.9.4. Estimated Sales Revenues

10.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
10.10.1. Therapy Overview
10.10.2. Clinical Trial Information
10.10.3. Clinical Trial Endpoints
10.10.4. Clinical Trial Results
10.10.5. Estimated Sales Revenues

10.11. AUTO3 / CD19/22 CAR-T (Autolus)
10.11.1. Therapy Overview
10.11.2. Clinical Trial Information
10.11.3. Clinical Trial Endpoints
10.11.4. Clinical Trial Results
10.11.5. Estimated Sales Revenues

11. TCR-BASED THERAPY PROFILES
11.1. Chapter Overview
11.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore)
11.2.1. Therapy Overview
11.2.2. Clinical Trial Information
11.2.3. Clinical Trial Endpoints
11.2.4. Clinical Trial Results
11.2.5. Estimated Sales Revenues

11.3. GSK3377794 / NY-ESO-1C259 T-Cells / Letetresgene Autoleucel (GlaxoSmithKline)
11.3.1. Therapy Overview
11.3.2. Clinical Trial Information
11.3.3. Clinical Trial Endpoints
11.3.4. Clinical Trial Results
11.3.5. Estimated Sales Revenues

11.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
11.4.1. Therapy Overview
11.4.2. Clinical Trial Information
11.4.3. Clinical Trial Endpoints
11.4.4. Clinical Trial Results
11.4.5. Estimated Sales Revenues

11.5. JTCR016 (Juno Therapeutics)
11.5.1. Therapy Overview
11.5.2. Clinical Trial Information
11.5.3. Clinical Trial Endpoints
11.5.4. Estimated Sales Revenues

11.6. TBI-1301 (Takara Bio)
11.6.1. Therapy Overview
11.6.2. Clinical Trial Information
11.6.3. Clinical Trial Endpoints
11.6.4. Clinical Trial Results
11.6.5. Estimated Sales Revenues

11.7. MDG1011 (Medigene)
11.7.1. Therapy Overview
11.7.2. Clinical Trial Information
11.7.3. Clinical Trial Endpoints
11.7.4. Clinical Trial Results
11.7.5. Estimated Sales Revenues

12. TIL-BASED THERAPY PROFILES
12.1. Chapter Overview
12.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
12.2.1. Therapy Overview
12.2.2. Clinical Trial Information
12.2.3. Clinical Trial Endpoints
12.2.4. Clinical Trial Results
12.2.5. Estimated Sales Revenues

12.3. LN-145 (Iovance Biotherapeutics)
12.3.1. Therapy Overview
12.3.2. Clinical Trial Information
12.3.3. Clinical Trial Endpoints
12.3.4. Clinical Trial Results
12.3.5. Estimated Sales Revenues

12.4. ITIL-168 (Instil Bio)
12.4.1. Therapy Overview
12.4.2. Clinical Trial Information
12.4.3. Clinical Trial Endpoints
12.4.4. Clinical Trial Results
12.4.5. Estimated Sales Revenues

12.5. LTX-315 (Lytix Biopharma)
12.5.1. Therapy Overview
12.5.2. Clinical Trial Information
12.5.3. Clinical Trial Endpoints
12.5.4. Clinical Trial Results
12.5.5. Estimated Sales Revenues

13. EMERGING TECHNOLOGIES
13.1. Chapter Overview
13.2. Genome Editing Technologies
13.2.1. Technology Overview
13.2.2. Applications of Genome Editing Technologies
13.2.3. Emerging Technology Platforms for T-Cell Therapies
13.2.3.1. CRISPR / CAS9 System
13.2.3.1.1. Key Components
13.2.3.1.2. Mechanism of Action
13.2.3.1.3. Targeting Efficiency and Challenges
13.2.3.1.4. Next-Gen CRISPR Technology

13.2.3.1.5. Technology Providers
13.2.3.1.5.1. Intellia Therapeutics
13.2.3.1.5.2. Editas Medicine
13.2.3.1.5.3. CRISPR Therapeutics
13.2.3.1.5.4. Beam Therapeutics
13.2.3.1.5.5. Gracell Technologies
13.2.3.1.5.6. Caribou Biosciences
13.2.3.1.5.7. Nanjing Bioheng Biotech
13.2.3.1.5.8. Intima Biosciences
13.2.3.1.5.9. KSQ Therapeutics
13.2.3.1.5.10. Refuge Biotechnologies

13.2.3.2. TALENS
13.2.3.2.1. Key Components and Function
13.2.3.2.2. Mechanism of Action
13.2.3.2.3. Advantages and Challenges
13.2.3.2.4. Technology Providers
13.2.3.2.4.1. Cellectis
13.2.3.2.4.2. Editas Medicine

13.2.3.3. MegaTAL
13.2.3.3.1. Mechanism of Action
13.2.3.3.2. Technology Providers
13.2.3.3.2.1. bluebird bio
13.2.3.3.2.2. Precision Biosciences

13.2.3.4. Zinc Finger Nuclease
13.2.3.4.1. Mechanism of Action
13.2.3.4.2. Technology Providers
13.2.3.4.2.1. Sangamo Therapeutics

13.2.4. Competitive Analysis: Gene Editing Platforms
13.3. Designing T-Cell Therapies with Improved Characteristics
13.3.1. Technologies for Targeting Multiple Cancers
13.3.1.1. Antibody Coupled T-Cell Receptor
13.3.1.1.1. Cogent Biosciences
13.3.1.2. NKR-T Platform
13.3.1.2.1. Celyad
13.3.1.2.2. Glycostem
13.3.1.2.3. CatamaranBio

13.3.2. Technologies for Improved Safety
13.3.2.1. Armored CAR and EGFRt Technology
13.3.2.1.1. Juno Therapeutics
13.3.2.2. Rheoswitch Therapeutic System
13.3.2.2.1. Intrexon
13.3.2.2.2. Precigen
13.3.2.3. Inducible Caspase 9 Safety Switch
13.3.2.3.1. Bellicum Pharmaceuticals
13.3.2.3.1.1. CaspaCIDe Technology
13.3.2.3.1.2. CIDeCAR Technology
13.3.2.3.1.3. GoCAR-T Technology

13.3.2.4. On-OFF Switch, Multiple Companies
13.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
13.3.2.4.2. On-OFF Switch (Theravectys)

13.3.2.5. Other Technologies to Improve CAR-T Safety
13.3.3. Allogeneic Technologies
13.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
13.3.3.2. Allogeneic Platform (CELYAD)
13.3.3.3. Allogeneic Platform (Cellectis)
13.3.3.4. AlloCAR T (Allogene Therapeutics)
13.4. Future Perspectives

14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Type of Product
14.3.4. Analysis by Year of Partnership and Type of Product
14.3.5. Analysis by Type of Partnership and Type of Product
14.3.6. Analysis by Type of Partner
14.3.7. Analysis by Type of Product and Type of Partner
14.3.8. Most Popular Products: Analysis by Number of Partnerships
14.3.9. Most Active Industry Players: Analysis by Number of Partnerships
14.3.10. Most Active Non-Industry Players: Analysis by Number of Partnerships
14.3.11. Analysis by Geography
14.3.11.1. Intercontinental and Intracontinental Agreements
14.3.11.2. International and Local Deals

15. FUNDING AND INVESTMENT ANALYSIS
15.1. Chapter Overview
15.2. Type of Funding
15.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
15.3.1. Analysis of Instances by Year
15.3.2. Analysis of Amount Invested by Year
15.3.3. Analysis by Type of Funding
15.3.4. Analysis of Amount Invested across Different Types of Therapies
15.3.5. Analysis by Type of Investor
15.3.6. Most Active Players: Analysis by Number of Instances
15.3.7. Most Active Investors: Analysis by Amount Invested
15.3.8. Analysis of Amount Invested by Geography
15.3.9. Most Active Investors: Analysis by Number of Funding Instances

16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Patent Analysis: Distribution by Type of Patent
16.4. CAR-T Cell Therapies: Patent Analysis
16.4.1. Analysis by Patent Publication Year
16.4.2. Analysis by Patent Application Year
16.4.3. Analysis by Geography
16.4.4. Analysis by Type of Player
16.4.5. Analysis by CPC Symbols
16.4.6. Analysis by Key Focus Area
16.4.7. Leading Players: Analysis by Number of Patents
16.4.8. Car-T Cell Therapies: Patent Benchmarking
16.4.9. Analysis By Patent Characteristics
16.4.10. Car-T Cell Therapies: Patent Valuation
16.5. TCR- based Therapies
16.5.1. Analysis by Patent Publication Year
16.5.2. Analysis By Patent Application Year
16.5.3. Analysis by Geography
16.5.4. Analysis by Type of Player
16.5.5. Analysis by CPC Symbols
16.5.6. Analysis by Key Focus Area
16.5.7. Leading Player: Analysis by Number of Patents
16.5.8. TCR-based Therapies: Patent Benchmarking
16.5.9. Analysis By Patent Characteristics
16.5.10. TCR-based Cell Therapies: Patent Valuation
16.6. TIL- based Therapies
16.6.1. Analysis by Patent Publication Year
16.6.2. Analysis By Patent Application Year
16.6.3. Analysis by Geography
16.6.4. Analysis by Type of Player
16.6.5. Analysis by CPC Symbols
16.6.6. Analysis by Key Focus Area
16.6.7. Leading Player: Analysis by Number of Patents
16.6.8. TIL-based Therapies: Patent Benchmarking
16.6.9. Analysis By Patent Characteristics
16.6.10. TIL-based Therapies: Patent Valuation

17. OTHER T-CELL IMMUNOTHERAPIES
17.1. Chapter Overview
17.2. Other T-Cell Immunotherapies
17.2.1. Fucosylated T-Cell Therapies
17.2.2. Gamma Delta T-Cell Therapies
17.2.3. PD-1 Knockout Engineered T-Cell Therapies
17.2.4. TAC T-Cell Therapies
17.2.5. T-Cell Vaccines
17.2.6. Treg Cell Therapies
17.2.7. Virus-Driven T-Cell Therapies

17.3. Other T-Cell Immunotherapies: Market Overview
17.3.1. Analysis by Type of T-Cell
17.3.2. Analysis by Source of T-Cell
17.3.3. Analysis by Phase of Development
17.3.4. Analysis by Therapeutic Area

17.4. Key Considerations for Developing T-Cell Immunotherapies
17.5. Concluding Remarks

18. CASE STUDY: CELL THERAPY MANUFACTURING
18.1. Chapter Overview
18.2. Overview of Cell Therapy Manufacturing
18.3. Cell Therapy Manufacturing Models
18.3.1. Centralized Manufacturing Model
18.3.2. Decentralized Manufacturing Model

18.4. Scalability of Cell Therapy Manufacturing Processes
18.4.1. Scale-Up
18.4.2. Scale-Out

18.5. Types of Cell Therapy Manufacturers
18.6. Key Challenges Related to Manufacturing of Cell Therapies

18.7. Important Factors for Cell Therapy Manufacturing
18.7.1. Characterization
18.7.2. Cost of Goods
18.8. Automation of Cell Therapy Manufacturing Process
18.9. Cell Therapy Manufacturing Supply Chain
18.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
18.11. Regulatory Landscape
18.12. Future Perspectives

19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing to the High Price of Cell / Gene Therapies
19.3. Pricing Models for T-Cell Immunotherapies
19.3.1. Based on Associated Costs
19.3.2. Based on Availability of Competing Products
19.3.3. Based on Patient Segment
19.3.4. Based on Opinions of Industry Experts

19.4. Reimbursement related Considerations for T-Cell Immunotherapies
19.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Key Assumptions And Forecast Methodology
20.4. Overall T-Cell Immunotherapy Market, 2022-2035
20.4.1. T-Cell Immunotherapy Market: Analysis by Type of Therapy
20.4.2. T-Cell Immunotherapy Market: Analysis by Target Indication
20.4.3. T-Cell Immunotherapy Market: Analysis by Target Antigen
20.4.4. T-Cell Immunotherapy Market: Analysis by Key Players
20.4.5. T-Cell Immunotherapy Market: Analysis by Geography
20.5. T-Cell Immunotherapy Market: Value Creation Analysis

20.6. Overall CAR-T Cell Therapies Market, 2022-2035
20.6.1. CAR-T Cell Therapies Market: Analysis by Target Indication
20.6.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
20.6.3. CAR-T Cell Therapies Market: Analysis by Key Players
20.6.4. CAR-T Cell Therapies Market: Analysis by Geography

20.6.5. Product Wise Sales Forecast
20.6.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
20.6.5.1.1. Sales Forecast (USD Million)
20.6.5.1.2. Net Present Value
20.6.5.1.3. Value Creation Analysis

20.6.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
20.6.5.2.1. Sales Forecast (USD Million)
20.6.5.2.2. Net Present Value (USD Million)
20.6.5.2.3. Value Creation Analysis

20.6.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
20.6.5.3.1. Sales Forecast (USD Million)
20.6.5.3.2. Net Present Value (USD Million)
20.6.5.3.3. Value Creation Analysis

20.6.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
20.6.5.4.1. Sales Forecast (USD Million)
20.6.5.4.2. Net Present Value (USD Million)
20.6.5.4.3. Value Creation Analysis

20.6.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
20.6.5.5.1. Sales Forecast (USD Million)
20.6.5.5.2. Net Present Value (USD Million)
20.6.5.5.3. Value Creation Analysis

20.6.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
20.6.5.6.1. Sales Forecast (USD Million)
20.6.5.6.2. Net Present Value (USD Million)
20.6.5.6.3. Value Creation Analysis

20.6.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
20.6.5.7.1. Sales Forecast (USD Million)
20.6.5.7.2. Net Present Value (USD Million)
20.6.5.7.3. Value Creation Analysis

20.6.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.8.1. Sales Forecast (USD Million)
20.6.5.8.2. Net Present Value (USD Million)
20.6.5.8.3. Value Creation Analysis

20.6.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
20.6.5.9.1. Sales Forecast (USD Million)
20.6.5.9.2. Net Present Value (USD Million)
20.6.5.9.3. Value Creation Analysis

20.6.5.10. Descartes-11 (Cartesian Therapeutics)
20.6.5.10.1. Sales Forecast (USD Million)
20.6.5.10.2. Net Present Value (USD Million)
20.6.5.10.3. Value Creation Analysis

20.6.5.11. Descartes-08 (Cartesian Therapeutics)
20.6.5.11.1. Sales Forecast (USD Million)
20.6.5.11.2. Net Present Value (USD Million)
20.6.5.11.3. Value Creation Analysis

20.6.5.12. Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine)
20.6.5.12.1. Sales Forecast (USD Million)
20.6.5.12.2. Net Present Value (USD Million)
20.6.5.12.3. Value Creation Analysis

20.6.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
20.6.5.13.1. Sales Forecast (USD Million)
20.6.5.13.2. Net Present Value (USD Million)
20.6.5.13.3. Value Creation Analysis

20.6.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
20.6.5.14.1. Sales Forecast (USD Million)
20.6.5.14.2. Net Present Value (USD Million)
20.6.5.14.3. Value Creation Analysis

20.6.5.15. TAK-007 (Takeda)
20.6.5.15.1. Sales Forecast (USD Million)
20.6.5.15.2. Net Present Value (USD Million)
20.6.5.15.3. Value Creation Analysis

20.6.5.16. AUTO1 (Autolus)
20.6.5.16.1. Sales Forecast (USD Million)
20.6.5.16.2. Net Present Value (USD Million)
20.6.5.16.3. Value Creation Analysis

20.6.5.17. AUTO3 (Autolus)
20.6.5.17.1. Sales Forecast (USD Million)
20.6.5.17.2. Net Present Value (USD Million)
20.6.5.17.3. Value Creation Analysis

20.6.5.18. CD19-CAR-T (Bioray Laboratories)
20.6.5.18.1. Sales Forecast (USD Million)
20.6.5.18.2. Net Present Value (USD Million)
20.6.5.18.3. Value Creation Analysis

20.6.5.19. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.19.1. Sales Forecast (USD Million)
20.6.5.19.2. Net Present Value (USD Million)
20.6.5.19.3. Value Creation Analysis

20.6.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
20.6.5.20.1. Sales Forecast (USD Million)
20.6.5.20.2. Net Present Value (USD Million)
20.6.5.20.3. Value Creation Analysis

20.6.5.21. CCT301 CAR-T (Shanghai PerHum Therapeutics)
20.6.5.21.1. Sales Forecast (USD Million)
20.6.5.21.2. Net Present Value (USD Million)
20.6.5.21.3. Value Creation Analysis

20.6.5.22. BinD19 (Shenzhen BinDeBio)
20.6.5.22.1. Sales Forecast (USD Million)
20.6.5.22.2. Net Present Value (USD Million)
20.6.5.22.3. Value Creation Analysis

20.6.5.23. CARCIK-CD19 (CoImmune)
20.6.5.23.1. Sales Forecast (USD Million)
20.6.5.23.2. Net Present Value (USD Million)
20.6.5.23.3. Value Creation Analysis

20.6.5.24. PBCAR269A (Precision BioSciences / Servier)
20.6.5.24.1. Sales Forecast (USD Million)
20.6.5.24.2. Net Present Value (USD Million)
20.6.5.24.3. Value Creation Analysis

20.6.5.25. CD123 CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.25.1. Sales Forecast (USD Million)
20.6.5.25.2. Net Present Value (USD Million)
20.6.5.25.3. Value Creation Analysis

20.6.5.26. BCMA CAR-T (Chongqing Precision Biotechnology)
20.6.5.26.1. Sales Forecast (USD Million)
20.6.5.26.2. Net Present Value (USD Million)
20.6.5.26.3. Value Creation Analysis

20.6.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.27.1. Sales Forecast (USD Million)
20.6.5.27.2. Net Present Value (USD Million)
20.6.5.27.3. Value Creation Analysis

20.6.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
20.6.5.28.1. Sales Forecast (USD Million)
20.6.5.28.2. Net Present Value (USD Million)
20.6.5.28.3. Value Creation Analysis

20.6.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
20.6.5.29.1. Sales Forecast (USD Million)
20.6.5.29.2. Net Present Value (USD Million)
20.6.5.29.3. Value Creation Analysis

20.6.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
20.6.5.30.1. Sales Forecast (USD Million)
20.6.5.30.2. Net Present Value (USD Million)
20.6.5.30.3. Value Creation Analysis

20.6.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
20.6.5.31.1. Sales Forecast (USD Million)
20.6.5.31.2. Net Present Value (USD Million)
20.6.5.31.3. Value Creation Analysis

20.6.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
20.6.5.32.1. Sales Forecast (USD Million)
20.6.5.32.2. Net Present Value (USD Million)
20.6.5.32.3. Value Creation Analysis

20.6.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
20.6.5.33.1. Sales Forecast (USD Million)
20.6.5.33.2. Net Present Value (USD Million)
20.6.5.33.3. Value Creation Analysis

20.6.5.34. CT053 (CARsgen Therapeutics)
20.6.5.34.1. Sales Forecast (USD Million)
20.6.5.34.2. Net Present Value (USD Million)
20.6.5.34.3. Value Creation Analysis

20.6.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
20.6.5.35.1. Sales Forecast (USD Million)
20.6.5.35.2. Net Present Value (USD Million)
20.6.5.35.3. Value Creation Analysis

20.6.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.36.1. Sales Forecast (USD Million)
20.6.5.36.2. Net Present Value (USD Million)
20.6.5.36.3. Value Creation Analysis

20.6.5.37. ALLO-605 (Allogene Therapeutics)
20.6.5.37.1. Sales Forecast (USD Million)
20.6.5.37.2. Net Present Value (USD Million)
20.6.5.37.3. Value Creation Analysis

20.6.5.38. WU CART 007 (Wugen)
20.6.5.38.1. Sales Forecast (USD Million)
20.6.5.38.2. Net Present Value (USD Million)
20.6.5.38.3. Value Creation Analysis

20.6.5.39. CT103A (Nanjing IASO Biotherapeutics)
20.6.5.39.1. Sales Forecast (USD Million)
20.6.5.39.2. Net Present Value (USD Million)
20.6.5.39.3. Value Creation Analysis

20.7. Overall TCR-based Therapies Market
20.7.1. TCR-Based Therapies Market: Analysis by Target Indication
20.7.2. TCR-Based Therapies Market: Analysis by Target Antigen
20.7.3. TCR-Based Therapies Market: Analysis by Key Players
20.7.4. TCR-Based Therapies Market: Analysis by Geography

20.7.5. Product Wise Sales Forecast
20.7.5.1 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore)
20.7.5.1.1. Sales Forecast (USD Million)
20.7.5.1.2. Net Present Value (USD Million)
20.7.5.1.3. Value Creation Analysis

20.7.5.2. GSK3377794 (GlaxoSmithKline)
20.7.5.2.1. Sales Forecast (USD Million)
20.7.5.2.2. Net Present Value (USD Million)
20.7.5.2.3. Value Creation Analysis

20.7.5.3. YT-E001 (China Immunotech)
20.7.5.3.1. Sales Forecast (USD Million)
20.7.5.3.2. Net Present Value (USD Million)
20.7.5.3.3. Value Creation Analysis

20.7.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
20.7.5.4.1. Sales Forecast (USD Million)
20.7.5.4.2. Net Present Value (USD Million)
20.7.5.4.3. Value Creation Analysis

20.7.5.5. EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma)
20.7.5.5.1. Sales Forecast (USD Million)
20.7.5.5.2. Net Present Value (USD Million)
20.7.5.5.3. Value Creation Analysis

20.7.5.6. NTLA-5001 (Intellia Therapeutics)
20.7.5.6.1. Sales Forecast (USD Million)
20.7.5.6.2. Net Present Value (USD Million)
20.7.5.6.3. Value Creation Analysis

20.7.5.7. TBI-1301 (Takara Bio)
20.7.5.7.1. Sales Forecast (USD Million)
20.7.5.7.2. Net Present Value (USD Million)
20.7.5.7.3. Value Creation Analysis

20.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
20.7.5.8.1. Sales Forecast (USD Million)
20.7.5.8.2. Net Present Value (USD Million)
20.7.5.8.3. Value Creation Analysis

20.7.5.9. FH-MCVA2TCR (TCRCure Biopharma)
20.7.5.9.1. Sales Forecast (USD Million)
20.7.5.9.2. Net Present Value (USD Million)
20.7.5.9.3. Value Creation Analysis

20.8. Overall TIL-Based Therapies Market
20.8.1. TIL-Based Therapies Market: Analysis by Target Indication
20.8.2. TIL-Based Therapies Market: Analysis by Key Players
20.8.3. TIL-Based Therapies Market: Analysis by Geography

20.8.3.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
20.8.3.1.1. Sales Forecast (USD Million)
20.8.3.1.2. Net Present Value (USD Million)
20.8.3.1.3. Value Creation Analysis

20.8.3.2. LN-145 (Iovance Biotherapeutics)
20.8.3.2.1. Sales Forecast (USD Million)
20.8.3.2.2. Net Present Value (USD Million)
20.8.3.2.3. Value Creation Analysis

20.8.3.3. LTX-315 and TILs (Lytix Biopharma)
20.8.3.3.1. Sales Forecast (USD Million)
20.8.3.3.2. Net Present Value (USD Million)
20.8.3.3.3. Value Creation Analysis

20.8.3.4. TILs (Prometheus Laboratories)
20.8.3.4.1. Sales Forecast (USD Million)
20.8.3.4.2. Net Present Value (USD Million)
20.8.3.4.3. Value Creation Analysis

20.8.3.5. Donor Lymphocyte Infusion (Incyte)
20.8.3.5.1. Sales Forecast (USD Million)
20.8.3.5.2. Net Present Value (USD Million)
20.8.3.5.3. Value Creation Analysis

20.8.3.6. ITIL-168 (Instil Bio)
20.8.3.6.1. Sales Forecast (USD Million)
20.8.3.6.2. Net Present Value (USD Million)
20.8.3.6.3. Value Creation Analysis

20.8.3.7. IOV-2001 (Iovance Biotherapeutics)
20.8.3.7.1. Sales Forecast (USD Million)
20.8.3.7.2. Net Present Value (USD Million)
20.8.3.7.3. Value Creation Analysis

20.8.3.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
20.8.3.8.1. Sales Forecast (USD Million)
20.8.3.8.2. Net Present Value (USD Million)
20.8.3.8.3. Value Creation Analysis

20.8.3.9. TILs (Bristol-Myers Squibb)
20.8.3.9.1. Sales Forecast (USD Million)
20.8.3.9.2. Net Present Value (USD Million)
20.8.3.9.3. Value Creation Analysis

21. PROMOTIONAL ANALYSIS
21.1. Chapter Overview
21.2. Channels Used for Promotional Campaigns
21.3. Summary of Product Website Analysis
21.4. Summary of Patient Support Services and Informative Downloads

21.5. Kymriah: Promotional Analysis
21.5.1. Drug Overview
21.5.2. Product Website Analysis
21.5.2.3. Informative Downloads
21.5.3. Patient Support Services

21.6. Yescarta: Promotional Analysis
21.6.1. Drug Overview
21.6.2. Product Website Analysis
21.6.2.3. Informative Downloads
21.6.3. Patient Support Services

21.7. Tecartus: Promotional Analysis
21.7.1. Drug Overview
21.7.2. Product Website Analysis
21.7.3. Patient Support Services

21.8. Breyanzi: Promotional Analysis
21.8.1. Drug Overview
21.8.2. Product Website Analysis
21.8.3. Patient Support Services

21.9. Abecma: Promotional Analysis
21.9.1. Drug Overview
21.9.2. Product Website Analysis
21.9.3. Patient Support Services

21.10. Carvykti: Promotional Analysis
21.10.1. Drug Overview
21.10.2. Product Website Analysis
21.10.3. Patient Support Services

21.11. Kimmtrak: Promotional Analysis
21.11.1. Drug Overview
21.11.2. Product Website Analysis
21.11.3. Patient Support Services

22. COMPANY PROFILES
22.1. Chapter Overview
22.2. Adaptimmune Therapeutics
22.3. Alaunos Therapeutics
22.4. Autolus
22.5. bluebird Bio
22.6. Bristol Myers Squibb
22.7. Carsgen Therapeutics
22.8. Cellectis
22.9. Cellular Biomedicine Group
22.10. Gilead Sciences
22.11. GlaxoSmithKline
22.12. Immatics
22.13. Immunocore
22.14. Innovative Cellular Therapeutics
22.15. Iovance Biotherapeutics
22.16. Kuur Therapeutics
22.17. Lion TCR
22.18. Noile-Immune Biotech
22.19. Novartis
22.20. Shanghai GeneChem
22.21. Sinobioway Cell Therapy
22.22. Takara Bio
22.23. Wellington Zhaotai Therapies
22.24. Zelluna immunotherapy

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Cell Therapies
24.2.1. Interview Transcript: Tim Oldham, Former Chief Executive Officer

24.3. Glycostem Therapeutics
24.3.1. Interview Transcript: Troels Jordansen, Chief Executive Officer

24.4. Gracell Biotechnologies
24.4.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer

24.5. Lion TCR
24.5.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer

24.6. TxCell
24.6.1. Interview Transcript: Miguel Forte, Chief Executive Officer

24.7. Kite Pharma
24.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs

24.8. Celyad
24.8.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology

24.9. Iovance Biotherapeutics
24.9.1. Interview Transcript: Peter Ho, Former Director, Process Development

24.10. Waisman Biomanufacturing
24.10.1. Interview Transcript: Brian Dattilo, Director, Business Development

24.11. Theravectys
24.11.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development

24.12. Changhai Hospital
24.12.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology

24.13. University of Colorado
24.13.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary (CAR-T Cell Therapies): Overall Market Landscape
Figure 2.2 Executive Summary (CAR-T Cell Therapies): Clinical Trial Analysis
Figure 2.3 Executive Summary (CAR-T Cell Therapies): Key Opinion Leaders
Figure 2.4 Executive Summary (CAR-T Cell Therapies): Partnerships and Collaborations
Figure 2.5 Executive Summary (CAR-T Cell Therapies): Funding and Investments
Figure 2.6 Executive Summary (CAR-T Cell Therapies): Patent Analysis
Figure 2.7 Executive Summary (CAR-T Cell Therapies): Market Forecast and Opportunity Analysis
Figure 2.8 Executive Summary (TCR-based Therapies): Overall Market Landscape
Figure 2.9 Executive Summary (TCR-based Therapies): Clinical Trial Analysis
Figure 2.10 Executive Summary (TCR-based Therapies): Key Opinion Leaders
Figure 2.11 Executive Summary (TCR-based Therapies): Partnerships and Collaborations
Figure 2.12 Executive Summary (TCR-based Therapies): Funding and Investments
Figure 2.13 Executive Summary (TCR-based Therapies): Patent Analysis
Figure 2.14 Executive Summary (TCR-based Therapies): Market Forecast and Opportunity Analysis
Figure 2.15 Executive Summary (TIL-based Therapies): Overall Market Landscape
Figure 2.16 Executive Summary (TIL-based Therapies): Clinical Trial Analysis
Figure 2.17 Executive Summary (TIL-based Therapies): Key Opinion Leaders
Figure 2.18 Executive Summary (TIL-based Therapies): Partnerships and Collaborations
Figure 2.19 Executive Summary (TIL-based Therapies): Funding and Investments
Figure 2.20 Executive Summary (TIL-based Therapies): Patent Analysis
Figure 2.21 Executive Summary (TIL-based Therapies): Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 3.11 TCR-based Therapies: Development Process
Figure 3.12 TIL-based Therapies: Development Process
Figure 3.13 T-Cell Immunotherapies: Benefits and Roadblocks
Figure 4.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 4.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 4.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR-T Cell Therapies: Distribution by Key Target Indications
Figure 4.6 CAR-T Cell Therapies: Distribution by Key Target Antigens
Figure 4.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 4.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 4.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Figure 4.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 4.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 TCR-based Therapies: Distribution by Type of Developer
Figure 5.2 TCR-based Therapies: Distribution by Phase of Development
Figure 5.3 TCR-based Therapies: Distribution by Therapeutic Area
Figure 5.4 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 5.5 TCR-based Therapies: Distribution by Key Target Indication
Figure 5.6 TCR-based Therapies: Distribution by Key Target Antigen
Figure 5.7 TCR-based Therapies: Distribution by Source of T-Cells
Figure 5.8 TCR-based Therapies: Distribution by Route of Administration
Figure 5.9 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Figure 5.10 TCR-based Therapies: Distribution by Dosing Frequency
Figure 5.11 TCR-based Therapies: Distribution by Target Patient Segment
Figure 5.12 TCR-based Therapies: Distribution by Type of Therapy
Figure 5.13 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Figure 5.14 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.15 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.16 TCR-based Therapy Developers: Distribution by Year of Establishment
Figure 5.17 TCR-based Therapy Developers: Distribution by Company Size
Figure 5.18 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 5.19 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 6.1 TIL-based Therapies: Distribution by Type of Developer
Figure 6.2 TIL-based Therapies: Distribution by Phase of Development
Figure 6.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 6.4 TIL-based Therapies: Distribution by Key Target Indications
Figure 6.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 6.6 TIL-based Therapies: Distribution by Route of Administration
Figure 6.7 TIL-based Therapies: Distribution by Dosing Frequency
Figure 6.8 TIL-based Therapies: Distribution by Target Patient Segment
Figure 6.9 TIL-based Therapies: Distribution by Type of Therapy
Figure 6.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 6.13 TIL-based Therapy Developers: Distribution by Company Size
Figure 6.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 6.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 7.2 TCR-based Therapies: Popular Targets in Hematological Malignancies
Figure 7.3 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 7.4 TCR-based Therapies: Popular Targets in Solid Tumors
Figure 7.5 CAR-Construction: Distribution by Generation of CAR
Figure 7.6 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.7 CAR-Construction: Distribution by Type of Virus Used
Figure 7.8 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.9 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 8.1 Clinical Trial Analysis: Scope and Methodology
Figure 8.2 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Figure 8.3 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.4 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.5 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.6 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.7 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.8 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.9 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.10 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.13 CAR-T Cell Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.14 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.15 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.16 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.17 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.18 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.19 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.20 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.21 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Figure 8.22 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.23 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.24 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.25 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.26 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.27 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.28 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.29 TCR-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.30 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.31 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.32 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.33 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.34 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.35 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Figure 8.36 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.37 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.38 TIL-based Therapies Clinical Trial Analysis: Distribution o by Trial Phase
Figure 8.39 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.40 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.41 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.42 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.43 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.44 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.45 TIL-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.46 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.47 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.48 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.49 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 9.1 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.2 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Figure 9.4 CAR-T Cell Therapies: Distribution by Geographical Location of KOLs
Figure 9.5 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.8 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.10 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.11 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.12 TCR-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.13 TCR-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.14 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.15 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.16 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.17 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.18 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.19 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.20 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.21 TIL-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.22 TIL-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.23 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.24 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.25 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.26 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.27 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 10.1 Kymriah®: Estimated Sales Revenues
Figure 10.2 Yescarta®: Estimated Sales Revenues
Figure 10.3 Tecartus™: Estimated Sales Revenues
Figure 10.4 Breyanzi®: Estimated Sales Revenues
Figure 10.5 Abecma®: Estimated Sales Revenues
Figure 10.6 Carvykti®: Estimated Sales Revenues
Figure 10.7 Carteyva: Estimated Sales Revenues
Figure 10.8 TBI-1501: Estimated Sales Revenues
Figure 10.9 AUTO1: Estimated Sales Revenues
Figure 10.10 AUTO3: Estimated Sales Revenues
Figure 11.1 Kimmtrak®: Estimated Sales Revenues
Figure 11.2 GSK3377794: Estimated Sales Revenues
Figure 11.3 ADP-A2M4: Estimated Sales Revenues
Figure 11.4 JTCR016: Estimated Sales Revenues
Figure 11.5 TBI-1301: Estimated Sales Revenues
Figure 11.6 MDG1011: Estimated Sales Revenues
Figure 12.1 LN-144: Estimated Sales Revenues
Figure 12.2 LN-145: Estimated Sales Revenues
Figure 12.3 ITIL-168: Estimated Sales Revenues
Figure 12.4 LTX-315: Estimated Sales Revenues
Figure 13.1 Genome Editing Technologies: Applications
Figure 13.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Therapies
Figure 13.3 TALENS: Mechanism of Action
Figure 13.4 MegaTAL: Mechanism of Action
Figure 13.5 Zinc Finger Nuclease: Mechanism of Action
Figure 13.6 Competitiveness Analysis: Gene Editing Platforms
Figure 13.7 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 13.8 Cellectis: Properties of Enhanced T-Cell Platform
Figure 13.9 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 14.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 14.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 14.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 14.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 14.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.8 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Figure 14.9 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Figure 14.10 Most Popular Products: Distribution by Number of Partnerships
Figure 14.11 Most Active Industry Players: Distribution by Number of Partnerships
Figure 14.12 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 14.13 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 14.14 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 15.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 15.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 15.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 15.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 15.5 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 - 2022 (USD Million)
Figure 15.6 Funding and Investments: Distribution by Types of Investors
Figure 15.7 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 15.8 Most Active Players: Distribution by Number of Instances
Figure 15.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 15.10 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 15.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.3 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.4 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.5 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.6 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 16.7 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Figure 16.8 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Figure 16.9 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.10 CAR-T Cell Therapies Patent Analysis: Key Focus Area
Figure 16.11 Leading Industry Players: Distribution by Number of Patents
Figure 16.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 16.15 Patent Analysis: Distribution by Patent Age
Figure 16.14 CAR-T Therapies: Patent Valuation Analysis
Figure 16.15 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.16 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.17 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.18 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.19 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.20 TCR-based Therapies Patent Analysis: Distribution by Geography
Figure 16.21 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.22 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.23 TCR-based Therapies Patent Analysis: Key Focus Area
Figure 16.24 Leading Industry Players: Distribution by Number of Patents
Figure 16.25 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.26 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.27 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.28 Patent Analysis: Distribution by Patent Age
Figure 16.29 TCR-based Therapies: Patent Valuation Analysis
Figure 16.30 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.31 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.32 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.33 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.34 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.35 TIL-based Therapies Patent Analysis: Distribution by Geography
Figure 16.36 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.37 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.38 TIL-based Therapies Patent Analysis: Key Focus Area
Figure 16.39 Leading Industry Players: Distribution by Number of Patents
Figure 16.40 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.41 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.42 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.43 Patent Analysis: Distribution by Patent Age
Figure 16.44 TIL-based Therapies: Patent Valuation Analysis
Figure 17.1 Mechanism of Action of Gamma Delta T-Cells
Figure 17.2 Mechanism of Action of PD-1 Knockout Engineered T-Cell Therapies
Figure 17.3 Functions of Treg Cells
Figure 17.4 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Figure 17.7 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Figure 17.5 Other T-Cell Immunotherapies: Distribution by Phase of Development
Figure 17.6 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Figure 18.1 Steps for Manufacturing Cell Therapies
Figure 18.2 Centralized Manufacturing: Process Model
Figure 18.3 Decentralized Manufacturing: Process Model
Figure 18.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 18.5 Cell Therapy: Challenges and Drivers
Figure 18.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 18.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 18.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 19.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 20.1 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Figure 20.2 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Figure 20.3 T-Cell Immunotherapy Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.4 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.5 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.6 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.7 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Figure 20.8 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.9 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.10 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.11 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.12 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 20.13 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.14 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.15 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.16 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 20.17 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.18 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.19 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.21 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.22 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.23 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 20.24 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 20.25 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.26 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 20.27 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.28 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.29 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.30 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.31 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.32 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.33 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 20.34 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 20.35 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 20.36 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.37 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.38 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.39 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.40 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 20.41 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.42 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.43 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.44 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.45 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.46 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.47 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.48 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.49 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Figure 20.50 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.51 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.52 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.53 TCR-Based Therapies Market: Distribution by Target Antigen , 2025 and 2035 (USD Billion)
Figure 20.54 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.55 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.56 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast, till 2035 (USD Million)
Figure 20.57 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Figure 20.58 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Figure 20.59 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.60 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.61 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.62 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.63 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.64 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.65 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.66 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.67 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Figure 20.68 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.69 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.70 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.71 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.72 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.73 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Figure 20.74 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.75 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.76 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.77 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 21.1 Channels Used for Promotional Campaigns
Figure 21.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 21.3 Product Website Analysis: Kymriah®, Messages for Healthcare Professionals
Figure 21.4 Product Website Analysis: Kymriah®, Messages for Patients
Figure 21.5 Product Website Analysis: Kymriah®, Patient Support Program
Figure 21.6 Product Website Analysis: Yescarta®, Messages for Healthcare Professionals
Figure 21.7 Product Website Analysis: Yescarta®, Messages for Patients
Figure 21.8 Product Website Analysis: Yescarta®, Kite Konnect
Figure 21.9 Product Website Analysis: Yescarta®, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 21.10 Product Website Analysis: Tecartus™, Messages for Healthcare Professionals
Figure 21.11 Product Website Analysis: Tecartus™, Messages for Patients
Figure 21.12 Product Website Analysis: Tecartus™, Kite Konnect
Figure 21.13 Product Website Analysis: Breyanzi®, Messages for Healthcare Professional
Figure 21.14 Product Website Analysis: Breyanzi®, Messages for Patients
Figure 21.15 Product Website Analysis: Breyanzi®, Cell Therapy 360
Figure 21.16 Product Website Analysis: Abecma®, Messages for Healthcare Professional
Figure 21.17 Product Website Analysis: Abecma®, Messages for Patients
Figure 21.18 Product Website Analysis: Abecma®, Cell Therapy 360
Figure 21.19 Product Website Analysis: Carvykti®, Messages for Healthcare Professional
Figure 21.20 Product Website Analysis: Carvykti®, Messages for Patients
Figure 21.21 Product Website Analysis: Carvykti®, MyCARVYKTI
Figure 21.22 Product Website Analysis: Kimmtrak®, Messages for Healthcare Professional
Figure 21.23 Product Website Analysis: Kimmtrak®, Messages for Patients
Figure 21.24 Product Website Analysis: Kimmtrak®, Kimmtrak Connect
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Clinical Trial Analysis
Figure 23.3 Concluding Remarks: Key Opinion Leaders
Figure 23.4 Concluding Remarks: Partnerships and Collaborations
Figure 23.5 Concluding Remarks: Funding and Investments Analysis
Figure 23.6 Concluding Remarks: Patent Analysis
Figure 23.7 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9 CAR-T Cell and TCR-based Therapies: Key Differences
Table 4.1 CAR-T Cell Therapies: Clinical Pipeline
Table 4.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 4.4 List of CAR-T cells Developers
Table 5.1 TCR-based Therapies: Clinical Pipeline
Table 5.2 TCR-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 5.3 TCR-based Therapies: Preclinical Pipeline
Table 5.4 List of TCR-based Developers,
Table 6.1 TIL-based Therapies: Clinical Pipeline
Table 6.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 6.3 TIL-based Therapies: Preclinical Pipeline
Table 6.4 List of TIL-based Developers
Table 7.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 10.1 CAR-T Cell Therapies: List of Therapies Profiled
Table 10.2 Therapy Profile: Kymriah® (Novartis)
Table 10.3 Kymriah®: Clinical Trial Information
Table 10.4 Kymriah®: Clinical Trial Endpoints
Table 10.5 Kymriah®: Clinical Trial Results
Table 10.6 Therapy Profile: Yescarta® (Gilead Sciences)
Table 10.7 Yescarta®: Clinical Trial Information
Table 10.8 Yescarta®: Clinical Trial Endpoints
Table 10.9 Yescarta®: Clinical Trial Results
Table 10.10 Therapy Profile: Tecartus™ (Gilead Sciences)
Table 10.11 Tecartus™: Clinical Trial Information
Table 10.12 Tecartus™: Clinical Trial Endpoints
Table 10.13 Tecartus™: Clinical Trial Results
Table 10.14 Therapy Profile: Breyanzi® (Bristol Myers Squibb)
Table 10.15 Breyanzi®: Clinical Trial Information
Table 10.16 Breyanzi®: Clinical Trial Endpoints
Table 10.17 Breyanzi®: Clinical Trial Results
Table 10.18 Therapy Profile: Abecma® (Bristol Myers Squibb)
Table 10.19 Abecma®: Clinical Trial Information
Table 10.20 Abecma®: Clinical Trial Endpoints
Table 10.21 Abecma®: Clinical Trial Results
Table 10.22 Therapy Profile: Carvykti™ (Janssen)
Table 10.23 Carvykti™: Clinical Trial Information
Table 10.24 Carvykti™: Clinical Trial Endpoints
Table 10.25 Carvykti™: Clinical Trial Results
Table 10.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 10.27 Carteyva: Clinical Trial Information
Table 10.28 Carteyva: Clinical Trial Endpoints
Table 10.29 Carteyva: Clinical Trial Results
Table 10.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 10.31 TBI-1501: Clinical Trial Information
Table 10.32 TBI-1501: Clinical Trial Endpoints
Table 10.33 Therapy Profile: AUTO1 (Autolus)
Table 10.34 AUTO1: Clinical Trial Information
Table 10.35 AUTO1: Clinical Trial Endpoints
Table 10.36 AUTO1: Clinical Trial Results
Table 10.37 Therapy Profile: AUTO3 (Autolus)
Table 10.38 AUTO3: Clinical Trial Information
Table 10.39 AUTO3: Clinical Trial Endpoints
Table 10.40 AUTO3: Clinical Trial Results
Table 11.1 TCR Cell Therapies: List of Therapies Profiled
Table 11.2 Therapy Profile: Kimmtrak (Immunocore)
Table 11.3 Kimmtrak: Clinical Trial Information
Table 11.4 Kimmtrak: Clinical Trial Endpoints
Table 11.5 Kimmtrak: Clinical Trial Results
Table 11.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
Table 11.7 GSK3377794: Clinical Trial Information
Table 11.8 GSK3377794: Clinical Trial Endpoints
Table 11.9 GSK3377794: Clinical Trial Results
Table 11.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
Table 11.11 ADP-A2M4: Clinical Trial Information
Table 11.12 ADP-A2M4: Clinical Trial Endpoints
Table 11.13 ADP-A2M4: Clinical Trial Results
Table 11.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
Table 11.15 JTCR016: Clinical Trial Information
Table 11.16 JTCR016: Clinical Trial Endpoints
Table 11.17 Therapy Profile: TBI-1301 (Takara Bio)
Table 11.18 TBI-1301: Clinical Trial Information
Table 11.19 TBI-1301: Clinical Trial Endpoints
Table 11.20 TBI-1301: Clinical Trial Results
Table 11.21 Therapy Profile: MDG1011 (Medigene)
Table 11.22 MDG1011: Clinical Trial Information
Table 11.23 MDG1011: Clinical Trial Endpoints
Table 11.24 MDG1011: Clinical Trial Results
Table 12.1 TIL Cell Therapies: List of Therapies Profiled
Table 12.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 12.3 LN-144: Clinical Trial Information
Table 12.4 LN-144: Clinical Trial Endpoints
Table 12.5 LN-144: Clinical Trial Results
Table 12.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 12.7 LN-145: Clinical Trial Information
Table 12.8 LN-145: Clinical Trial Endpoints
Table 12.9 LN-145: Clinical Trial Results
Table 12.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 12.11 ITIL-168: Clinical Trial Information
Table 12.12 ITIL-168: Clinical Trial Endpoints
Table 12.13 ITIL-168: Clinical Trial Results
Table 12.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 12.15 LTX-315: Clinical Trial Information
Table 12.16 LTX-315: Clinical Trial Endpoints
Table 12.17 LTX-315: Clinical Trial Results
Table 13.1 Bellicum Pharmaceuticals: Key Switch Technologies
Table 13.2 Technologies For CAR-T Safety Enhancement
Table 14.1 T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2005-2022
Table 15.1 T-Cell Immunotherapies: Funding and Investments, 2000-2022
Table 15.2 T-Cell Immunotherapies: Summary of Investments
Table 16.1 CART-Cell Therapy Patent Analysis: Prominent CPC Symbols
Table 16.2 CART-Cell Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.3 CART-Cell Therapy Patent Analysis: List of Top CPC Symbols
Table 16.4 CART-Cell Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.5 CART-Cell Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.6 TCR-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.7 TCR-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.8 TCR-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.9 TCR-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.10 TCR-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.11 TIL-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.12 TIL-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.13 TIL-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.14 TIL-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.15 TIL-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.1 Characteristic Properties of Treg Cells
Table 17.2 Other T-Cell Immunotherapies: Therapy Candidate Pipeline
Table 18.1 Assessment Strategies for Different Manufacturing Processes
Table 18.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 18.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 19.1 Price of Marketed Gene / Cell Therapies
Table 19.2 Price of Marketed Targeted Drugs
Table 19.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 19.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 20.1 T-Cell Immunotherapies: List of Forecasted Molecules
Table 20.2 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Net Present Value (USD Million)
Table 20.3 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Value Creation Analysis (USD Million)
Table 20.4 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Net Present Value (USD Million)
Table 20.5 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.6 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Net Present Value (USD Million)
Table 20.7 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.8 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.9 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.10 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Net Present Value (USD Million)
Table 20.11 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Value Creation Analysis (USD Million)
Table 20.12 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.13 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.14 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 20.15 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 20.16 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.17 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 20.21 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 20.22 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.23 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.24 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.25 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.26 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 20.27 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 20.28 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 20.29 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 20.30 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 20.31 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 20.32 TAK-007 (Takeda): Net Present Value (USD Million)
Table 20.33 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 20.34 AUTO1 (Autolus): Net Present Value (USD Million)
Table 20.35 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 20.36 AUTO3 (Autolus): Net Present Value (USD Million)
Table 20.37 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 20.38 CD19-CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 20.39 CD19-CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 20.40 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.41 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.42 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 20.43 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 20.44 CCT301 CAR-T (Shanghai PerHum Therapeutics): Net Present Value (USD Million)
Table 20.45 CCT301 CAR-T (Shanghai PerHum Therapeutics): Value Creation Analysis (USD Million)
Table 20.46 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 20.47 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 20.48 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 20.49 CARCIK-CD19 (CoImmune): Value Creation Analysis (USD Million)
Table 20.50 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 20.51 PBCAR269A (Precision BioSciences / Servier): Value Creation Analysis (USD Million)
Table 20.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.54 BCMA CAR-T (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.55 BCMA CAR-T (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.57 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.58 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 20.59 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 20.60 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 20.61 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 20.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.63 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.64 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 20.65 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 20.66 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.67 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.69 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.70 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 20.71 CT053 (CARsgen Therapeutics)): Value Creation Analysis (USD Million)
Table 20.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.73 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.75 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.76 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.77 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.78 WU CART 007 (Wugen): Net Present Value (USD Million)
Table 20.79 WU CART 007 (Wugen): Value Creation Analysis (USD Million)
Table 20.80 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 20.81 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.82 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Net Present Value (USD Million)
Table 20.83 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Value Creation Analysis (USD Million)
Table 20.84 GSK3377794 (GlaxoSmithKline): Net Present Value (USD Million)
Table 20.85 GSK3377794 (GlaxoSmithKline): Value Creation Analysis (USD Million)
Table 20.86 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 20.87 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 20.88 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Net Present Value (USD Million)
Table 20.89 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
Table 20.90 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.91 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.92 NTLA-5001 (Intellia Therapeutics): Net Present Value (USD Million)
Table 20.93 NTLA-5001 (Intellia Therapeutics): Value Creation Analysis (USD Million)
Table 20.94 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 20.95 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 20.96 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 20.97 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 20.98 FH-MCVA2TCR (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.99 FH-MCVA2TCR (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.100 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.101 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.102 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.103 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.104 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 20.105 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 20.106 TILs (Prometheus Laboratories): Net Present Value (USD Million)
Table 20.107 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
Table 20.108 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 20.109 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 20.110 ITIL-168 (Instil Bio): Net Present Value (USD Million)
Table 20.111 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
Table 20.112 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.113 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.114 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 20.115 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 20.116 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 20.117 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 21.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 21.2 Kymriah®: Drug Overview
Table 19.3 Yescarta®: Drug Overview
Table 21.4 Tecartus™: Drug Overview
Table 21.5 Breyanzi®: Drug Overview
Table 21.6 Abecma®: Drug Overview
Table 21.7 Carvykti™: Drug Overview
Table 21.8 Kimmtrak®: Drug Overview
Table 22.1 Leading T-Cell Immunotherapy Developers
Table 22.2 Adaptimmune Therapeutics: Company Profile
Table 22.3 Alaunos Therapeutics: Company Profile
Table 22.4 Autolus: Company Profile
Table 22.5 bluebird bio: Company Profile
Table 22.6 Bristol Myers Squibb: Company Profile
Table 22.7 CARsgen Therapeutics: Company Profile
Table 22.8 Cellectis: Company Profile
Table 22.9 Cellular Biomedicine Group: Company Profile
Table 22.10 Gilead Sciences: Company Profile
Table 22.11 GlaxoSmith Kline: Company Profile
Table 22.12 Immatics: Company Profile
Table 22.13 Immunocore: Company Profile
Table 22.14 Innovative Cellular Therapeutics: Company Profile
Table 22.15 Iovance Biotherapeutics: Company Profile
Table 22.16 Kuur Therapeutics: Company Profile
Table 22.17 Lion TCR: Company Profile
Table 22.18 Noile-Immune Biotech: Company Profile
Table 22.19 Novartis: Company Profile
Table 22.20 Shanghai Genechem: Company Profile
Table 22.21 Sinobioway Cell Therapy: Company Profile
Table 22.22 Takara Bio: Company Profile
Table 22.23 Wellington Zhaotai Therapies: Company Profile
Table 22.24 Zelluna Immunotherapy: Company Profile
Table 25.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 25.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 25.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Table 25.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.5 CAR-T Cell Therapies: Distribution by Key Target Indication
Table 25.6 CAR-T Cell Therapies: Distribution by Key Target Antigen
Table 25.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 25.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Table 25.9 CAR-T Cell Therapies: Distribution by Route of Administration
Table 25.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Table 25.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 25.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 25.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 25.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 25.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Table 25.19 TCR-based Therapies: Distribution by Type of Developer
Table 25.20 TCR-based Therapies: Distribution by Phase of Development
Table 25.21 TCR-based Therapies: Distribution by Therapeutic Area
Table 25.22 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.23 TCR-based Therapies: Distribution by Key Target Indication
Table 25.24 TCR-based Therapies: Distribution by Key Target Antigen
Table 25.25 TCR-based Therapies: Distribution by Source of T-Cells
Table 25.26 TCR-based Therapies: Distribution by Route of Administration
Table 25.27 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Table 25.28 TCR-based Therapies: Distribution by Dosing Frequency
Table 25.29 TCR-based Therapies: Distribution by Target Patient Segment
Table 25.30 TCR-based Therapies: Distribution by Type of Therapy
Table 25.31 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Table 25.32 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Table 25.33 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Table 25.34 TCR-based Therapy Developers: Distribution by Year of Establishment
Table 25.35 TCR-based Therapy Developers: Distribution by Company Size
Table 25.36 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.37 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.38 TIL-based Therapies: Distribution by Type of Developer
Table 25.39 TIL-based Therapies: Distribution by Phase of Development
Table 25.40 TIL-based Therapies: Distribution by Therapeutic Area
Table 25.41 TIL-based Therapies: Distribution by Key Target Indications
Table 25.42 TIL-based Therapies: Distribution by Source of T-Cells
Table 25.43 TIL-based Therapies: Distribution by Route of Administration
Table 25.44 TIL-based Therapies: Distribution by Dosing Frequency
Table 25.45 TIL-based Therapies: Distribution by Target Patient Segment
Table 25.46 TIL-based Therapies: Distribution by Type of Therapy
Table 25.47 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Table 25.48 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Table 25.49 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 25.50 TIL-based Therapy Developers: Distribution by Company Size
Table 25.51 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.52 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.53 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Table 25.54 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.55 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.56 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.57 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.58 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.59 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.60 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.61 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.62 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.63 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.64 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.65 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.66 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.67 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.68 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-20172022
Table 25.69 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.70 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.71 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Table 25.72 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.73 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.74 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.75 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.76 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.77 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.78 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.79 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.80 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.81 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.82 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.83 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Table 25.84 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Table 25.85 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.86 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.87 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.88 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.89 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.90 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.91 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.92 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.93 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.94 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.95 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.96 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.97 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.98 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 25.99 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.100 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Table 25.101 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.102 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.103 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.104 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.105 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.106 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.107 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.108 TCR-based Therapies KOL Analysis: Distribution by Qualification
Table 25.109 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.110 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.111 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.112 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.113 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.114 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.115 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.116 TIL-based Therapies KOL Analysis: Distribution by Qualification
Table 25.117 TIL-based Therapies: Geographical Distribution of KOLs
Table 25.118 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.119 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.120 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.121 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.122 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.123 Kymriah®: Estimated Sales Revenues
Table 25.124 Yescarta®: Estimated Sales Revenues
Table 25.125 Tecartus™: Estimated Sales Revenues
Table 25.126 Breyanzi®: Estimated Sales Revenues
Table 25.127 Abecma®: Estimated Sales Revenues
Table 25.128 Carvykti®: Estimated Sales Revenues
Table 25.129 Carteyva: Estimated Sales Revenues
Table 25.130 TBI-1501: Estimated Sales Revenues
Table 25.131 AUTO1: Estimated Sales Revenues
Table 25.132 AUTO3: Estimated Sales Revenues
Table 25.133 Kimmtrak®: Estimated Sales Revenues
Table 25.134 GSK3377794: Estimated Sales Revenues
Table 25.135 ADP-A2M4: Estimated Sales Revenues
Table 25.136 JTCR016: Estimated Sales Revenues
Table 25.137 TBI-1301: Estimated Sales Revenues
Table 25.138 MDG1011: Estimated Sales Revenues
Table 25.139 LN-144: Estimated Sales Revenues
Table 25.140 LN-145: Estimated Sales Revenues
Table 25.141 ITIL-168: Estimated Sales Revenues
Table 25.142 LTX-315: Estimated Sales Revenues
Table 25.143 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 25.144 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.145 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 25.146 Partnerships and Collaborations: Distribution by Type of Product
Table 25.147 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Therapy
Table 25.148 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 25.149 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.150 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 25.151 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Table 25.152 Most Popular Products: Distribution by Number of Partnerships
Table 25.153 Most Active Industry Players: Distribution by Number of Partnerships
Table 25.154 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 25.155 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 25.156 Partnerships and Collaborations: Distribution of International and Local Deals
Table 25.157 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 25.158 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 25.159 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 25.160 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 25.161 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 – 2022 (USD Million)
Table 25.162 Funding and Investments: Distribution by Types of Investors
Table 25.163 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 25.164 Most Active Players: Distribution by Number of Instances
Table 25.165 Most Active Players: Distribution by Amount Invested
Table 25.166 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 25.167 Most Active Investors: Distribution by Number of Funding Instances
Table 25.168 Patent Analysis: Distribution by Type of Patent
Table 25.169 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.170 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.171 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.172 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.173 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 25.174 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Table 25.175 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Table 25.176 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.177 Leading Industry Players: Distribution by Number of Patents
Table 25.178 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.179 Leading Patent Assignees: Distribution by Number of Patents
Table 25.180 Patent Analysis: Distribution by Patent Age
Table 25.181 CAR-T Therapies: Patent Valuation Analysis
Table 25.182 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.183 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.184 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.185 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.186 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Table 25.187 TCR-based Therapies Patent Analysis: Distribution by Geography
Table 25.188 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.189 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.190 Leading Industry Players: Distribution by Number of Patents
Table 25.191 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.192 Leading Patent Assignees: Distribution by Number of Patents
Table 25.193 Patent Analysis: Distribution by Patent Age
Table 25.194 TCR-based Therapies: Patent Valuation Analysis
Table 25.195 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.196 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.197 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.198 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.199 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted patents
Table 25.200 TIL-based Therapies Patent Analysis: Distribution by Geography
Table 25.201 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.202 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.203 Leading Industry Players: Distribution by Number of Patents
Table 25.204 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.205 Leading Patent Assignees: Distribution by Number of Patents
Table 25.206 Patent Analysis: Distribution by Patent Age
Table 25.207 TIL-based Therapies: Patent Valuation Analysis
Table 25.208 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Table 25.209 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Table 25.210 Other T-Cell Immunotherapies: Distribution by Phase of Development
Table 25.211 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Table 25.212 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Table 25.213 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Table 25.214 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Table 25.215 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035
Table 25.216 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.217 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.218 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Table 25.219 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.220 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.221 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.222 CAR-T Cell Therapies Market: Distribution by Target Geography, 2025 and 2035 (USD Billion)
Table 25.223 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Table 25.224 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.225 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.226 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.227 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Table 25.228 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.229 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.230 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.231 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Table 25.232 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.233 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.234 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Table 25.235 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Table 25.236 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.237 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Table 25.238 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.239 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.240 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.241 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.242 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast till 2035 (USD Million)
Table 25.243 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.244 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Table 25.245 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Table 25.246 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Table 25.247 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.248 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.249 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.250 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.251 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Table 25.252 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.253 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.254 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.255 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.256 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.257 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.258 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.259 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.260 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Table 25.261 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.262 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Table 25.263 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.264 TCR-Based Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.265 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.266 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.267 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales
Table 25.268 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Table 25.269 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Table 25.270 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.271 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.272 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.273 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Table 25.274 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, 2035 (USD Million)
Table 25.275 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.276 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Table 25.277 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.278 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Table 25.279 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.280 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.281 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.282 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.283 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.284 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Table 25.285 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Table 25.286 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.287 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.288 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 2seventy bio
  2. 3E Bioventures Capital
  3. 5AM Ventures
  4. 6 Dimensions Capital
  5. 8VC
  6. 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 
  7. Academy of Military Medical Sciences
  8. AbbVie Ventures
  9. AbCellera
  10. AbCheck
  11. AbClon
  12. Abingworth
  13. Abound Bio
  14. AbVitro
  15. Abzena
  16. Atunizade
  17. Ac?badem Labcell
  18. Acibadem University
  19. Acorn Bioventures
  20. ACROBiosystems
  21. Actinium Pharmaceuticals
  22. Adage Capital Management
  23. AdAlta
  24. Adaptimmune Therapeutics
  25. Adicet Bio
  26. Adimab
  27. Affiliated Hospital of Jiangnan University
  28. Affiliated Hospital of Jiangsu University
  29. Affiliated Hospital to Academy of Military Medical Sciences
  30. Affiliated Zhongshan Hospital of Dalian University
  31. AffyImmune Therapeutics
  32. AGC Biologics
  33. Agency for Science, Technology and Research (A*STAR)
  34. Agent Capital
  35. AgonOx
  36. Agreen Biotech
  37. Aisling Capital
  38. AK (Suzhou) Biomedical
  39. Alaunos Therapeutics
  40. Aleta Biotherapeutics
  41. Alex’s Lemonade Stand Foundation
  42. Alexandria Venture Investments
  43. Alpha Wave Global (Formerly known as Falcon Edge Capital)
  44. Allife Medical Science and Technology
  45. Allogene Therapeutics
  46. Alpha Biopharma
  47. Alpine Immune Sciences
  48. ALSHC
  49. Americo
  50. Amgen Ventures
  51. Andera Partners
  52. Anhui Anke Biotechnology
  53. Anhui Provincial Hospital
  54. Anocca
  55. Antion Biosciences
  56. Apeiron Investment Group
  57. Appia Bio
  58. Applied DNA Sciences
  59. Aquilo Capital Management
  60. ARBELE
  61. Arbor Biotechnologies
  62. Arcellx
  63. ARCH Venture Partners
  64. Arix Bioscience
  65. ArrowMark Partners
  66. Astellas Pharma
  67. Astellas Venture Management
  68. Astero Bio
  69. AstraZeneca
  70. Asymmetry Asset Management
  71. Asymptote
  72. Atara Biotherapeutics
  73. ATEM Capital
  74. Athenex
  75. Atlas Venture
  76. August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
  77. Aurora Biopharma
  78. Autolus
  79. Avego BioScience Capital
  80. AvenCell
  81. AVICT Global
  82. Avidity Partners
  83. B Capital Group
  84. Bambino Gesù Hospital and Research Institute
  85. Bayer
  86. Baylor College of Medicine
  87. Be The Match BioTherapies
  88. Beam Therapeutics
  89. Beijing 302 Hospital
  90. Beijing Biohealthcare Biotechnology
  91. Beijing Boren Hospital
  92. Beijing Cancer Hospital
  93. Beijing Chaoyang Hospital
  94. Beijing Children's Hospital
  95. Beijing Doing Biomedical
  96. Beijing GoBroad Hospital Management
  97. Beijing HuiNengAn Biotech
  98. Beijing Immunochina Medical Science & Technology
  99. Beijing Lu Daopei Hospital
  100. Beijing Mario Biotech
  101. Beijing Sanbo Brain Hospital
  102. Beijing Tsinghua Chang Gung Hospital
  103. Beike Biotechnology
  104. Bellicum Pharmaceuticals
  105. Berlin Institute of Health
  106. Bessemer Venture Partners
  107. Beth Israel Deaconess Medical Center (BIDMC)
  108. BiGEN
  109. BINEX
  110. Bioceltech Therapeutics
  111. BioCopy
  112. Bio-Gene Technology
  113. BioLife Solutions
  114. Bionomics
  115. BioNTech
  116. Bioray Laboratories
  117. Biosceptre
  118. BlackRock
  119. Blackstone Life Sciences
  120. Blood Centers of America
  121. bluebird bio
  122. BlueRun Ventures
  123. Boxer Capital
  124. Boya Jiyin
  125. BoYuan RunSheng Pharma (Hangzhou)
  126. Brace Pharma Capital
  127. Brigham & Women’s Hospital
  128. Bristol-Myers Squibb
  129. British Patient Capital
  130. Broad Institute
  131. Bukwang Pharmaceutical
  132. BVCF Management
  133. CaaS Capital Management
  134. Cabaletta Bio
  135. Cabaret Biotech
  136. Calibr
  137. California Institute for Regenerative Medicine (CIRM)
  138. California Institute of Technology
  139. CAM Capital
  140. Cambrian Biopharma
  141. Canaan Partners
  142. Cancer Prevention Research Institute of Texas
  143. Cancer Research Technology
  144. Cancer Research UK
  145. Carbiogene Therapeutics
  146. Cardiff University
  147. Caribou Biosciences
  148. Carina Biotech
  149. Caring Cross
  150. CARISMA Therapeutics
  151. CARsgen Therapeutics
  152. CAR-T (Shanghai) Cell Biotechnology
  153. Cartesian Therapeutics
  154. Cartherics
  155. Casdin Capital
  156. Case Comprehensive Cancer Center 
  157. Casebia Therapeutics
  158. Catalio Capital Management
  159. CCB International
  160. CDH Investments
  161. Celdara Medical
  162. Celgene
  163. Cell and Gene Therapy Catapult
  164. Cell Design Labs
  165. Cellares
  166. Cellectis
  167. Cellex Patient Treatment 
  168. CELLforCURE
  169. CellPoint
  170. Cellular Biomedicine Group
  171. Cellular Therapeutics
  172. CellVec
  173. Celularity
  174. Celyad Oncology
  175. Center for International Blood and Marrow Transplant Research
  176. Central South University
  177. Changhai Hospital
  178. Charité – Universitätsmedizin Berlin
  179. Chengdu International Bio-Town Investment and Development
  180. Chengdu USino Technology Biology
  181. Children’s Hospital of Philadelphia
  182. Children's Hospital Foundation
  183. Children's Hospital of Fudan University
  184. Children's Hospital of Philadelphia
  185. China Everbright
  186. China Immunotech (Beijing) Biotechnology
  187. China Meitan General Hospital
  188. China Regenerative Medicine International (CRMI)
  189. China Resources Innovative Equity Investment Fund
  190. China (Nanjing) Cell Valley
  191. Chinese Academy of Sciences
  192. Chinese PLA General Hospital
  193. Chongqing Precision Biotech
  194. Chongqing Public Health Medical Center
  195. Chongqing Sidemu Biotechnology Technology
  196. Chongqing University Cancer Hospital
  197. CICC
  198. City of Hope National Medical Center
  199. Clough Capital
  200. CMG-SDIC Capital
  201. CNCB Capital
  202. Cognate BioServices
  203. CoImmune
  204. Cold Spring Harbor Laboratory
  205. Columbia University
  206. Column Group Crossover Fund
  207. Cormorant Asset Management
  208. Corregene Biotechnology
  209. CoStone Capital
  210. Cowen
  211. Co-win Ventures
  212. CPE Capital
  213. CR-CP Life Science Fund
  214. CRISPR Therapeutics
  215. Cryoport
  216. CTM CRC
  217. Curative Ventures
  218. CureSearch for Children's Cancer
  219. Curocell 
  220. CytoLumina Technologies
  221. CytoMed Therapeutics
  222. Cytovant Sciences
  223. Cytovia Therapeutics
  224. Dai-ichi Life
  225. Daiichi Sankyo
  226. Dalton Capital
  227. Dalton Venture
  228. Dana-Farber Cancer Institute
  229. Danske Bank
  230. Dartmouth College
  231. Daxie Pengchuang Investment
  232. Decheng Capital
  233. Deep Track Capital
  234. Deerfield Management
  235. Deguan Capital
  236. Delenex Therapeutics
  237. Delian Capital
  238. Direct Selling Association of Malaysia (DSAM)
  239. Ditch Plains Capital Management
  240. German Aerospace Center (DLR)
  241. Dongguan People's Hospital
  242. Droia Ventures
  243. DS Asset Management
  244. Duke Management Company
  245. Duke-NUS Medical School
  246. Dutch Cancer Society
  247. Earle A. Chiles Research Institute
  248. EcoR1 Capital
  249. Eden BioCell
  250. Editas Medicine
  251. Efung Capital
  252. Ehime University
  253. Eli Lilly
  254. Elicera Therapeutics
  255. Elikon Venture
  256. Elpis Biopharmaceuticals
  257. Emerson Collective
  258. Epidarex Capital
  259. EQT Life Sciences
  260. Erasmus MC
  261. Etcembly
  262. Eureka Therapeutics
  263. European Commission
  264. Eutilex
  265. Eventide Asset Management
  266. EXUMA Biotech
  267. Farallon Capital Management
  268. Fate Therapeutics
  269. Federal Research Institute of Pediatric Hematology, Oncology and Immunology
  270. FetoLumina Technologies
  271. Fidelity Biosciences
  272. Fidelity Management & Research
  273. Fidim 
  274. First Affiliated Hospital of Chengdu Medical College
  275. First Affiliated Hospital of Harbin Medical University
  276. First Affiliated Hospital of Jinan University
  277. First Affiliated Hospital of Wenzhou Medical University
  278. First Affiliated Hospital of Zhejiang University
  279. First Affiliated Hospital Xi'an Jiaotong University
  280. First Affiliated Hospital, Sun Yat-sen University
  281. First Hospital of Jilin University
  282. First People's Hospital of Foshan
  283. First People's Hospital of Changzhou 
  284. Five Prime Therapeutics
  285. Fiverings
  286. Flagship Ventures
  287. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  288. European Social Fund 
  289. Fondos ARI (Assistencia Recerca Intensiva)
  290. Foresite Capital
  291. Fortress Biotech (Formerly known as Coronado Biosciences)
  292. Formula Pharmaceuticals
  293. Fortress Investment 
  294. Fosun Pharmaceutical
  295. Fourth Hospital of Hebei Medical University
  296. F-Prime
  297. Franklin Templeton
  298. Fraunhofer
  299. Fred Hutchinson Cancer Research Center
  300. Fudan University
  301. Fujian Medical University
  302. Fujifilm
  303. Fujita Health University
  304. Fundamenta Therapeutics
  305. Future Ventures
  306. FutureGen Biopharm
  307. G.N. Tech Venture
  308. Gadeta
  309. GC LabCell
  310. GE Global Research
  311. GE Healthcare
  312. Gene Therapy Center
  313. Genentech
  314. Genezen
  315. Genmab
  316. Genocea Biosciences
  317. Genome Institute of Singapore
  318. Genus Oncology
  319. Gencells Therapeutics
  320. GIC
  321. GigaGen
  322. Gilead Sciences
  323. GL Ventures
  324. GlaxoSmithKline
  325. Glycostem Therapeutics
  326. GlyTherix
  327. Google Ventures
  328. Gracell Biotechnologies
  329. Great Ormond Street Hospital for Children NHS Foundation Trust 
  330. Green Cross Holdings
  331. Gritstone Oncology
  332. Guangdong Chongye Holdings
  333. Guangdong General Hospital
  334. Guangdong Xiangxue Precision Medical Technology
  335. Guangdong Zhaotai InVivo Biomedicine
  336. Guangzhou Eighth People's Hospital
  337. Guangzhou Anjie Biomedical Technology
  338. Guangzhou FineImmune Biotechnology
  339. Guangzhou First People's Hospital
  340. Guangzhou Institute of Respiratory Disease
  341. GV
  342. H. Lee Moffitt Cancer Center and Research Institute
  343. H. Lee Moffitt Cancer Center and Research Institute
  344. H.C. Wainwright & Co.
  345. Hadassah Medical Organization
  346. Haitong International Securities
  347. Harvard University
  348. HCW Biologics
  349. Hebei Senlang Biotechnology
  350. Hebei Yanda Ludaopei Hospital
  351. Hefei Binhu Hospital
  352. Heidelberg University Hospital
  353. Helmholtz Zentrum München
  354. Henan Cancer Hospital
  355. Henan Hualong Biotechnology
  356. Henan Provincial People's Hospital
  357. Hengzhen Investment
  358. Heritage Medical Systems
  359. Herlev Hospital
  360. HiFiBiO Therapeutics
  361. Hillhouse Capital
  362. Hitachi Chemical Advanced Therapeutics Solutions
  363. Horizon 2020
  364. Horizon Discovery
  365. Horizon Technology Finance
  366. Houston Methodist Hospital
  367. Howard Hughes Medical Institute
  368. Hrain Biotechnology
  369. HuaDao (Shanghai) Biomedical
  370. Huazhong University of Science and Technology
  371. Hudson Bay Capital Management
  372. Hunan Provincial People's Hospital
  373. Hunan Yongren Medical Innovation
  374. Hunan Zhaotai Yongren Biotech
  375. Hunan Zhaotai Yongren Medical Innovation
  376. Huzhou Jiuli Industrial Investment
  377. IASO Biotherapeutics
  378. iCAR Bio Therapeutics
  379. iCarTAB BioMed
  380. iCell Gene Therapeutics
  381. ICON
  382. IIT MediTech (Jiangsu)
  383. Immatics
  384. Immatics Biotechnologies
  385. Immetacyte
  386. ImmunoACT
  387. Immunocore
  388. Immunotech Biopharm
  389. Immunotherapy Foundation
  390. Imperial Innovations
  391. Imugene
  392. Incyte
  393. Inhibrx
  394. Innovative Cellular Therapeutics
  395. Innovent Biologics
  396. Instil Bio
  397. Institut Curie
  398. Institute of Hematology & Blood Diseases Hospital
  399. Institute of Hematology and Blood Transfusion
  400. Instituto de Salud Carlos III
  401. Intellia Therapeutics
  402. Intermediate Capital (ICG)
  403. Intima Bioscience
  404. Intrexon
  405. Invectys
  406. Invesco Perpetual
  407. Invus
  408. Iovance Biotherapeutics
  409. IRICoR
  410. Janssen
  411. Janus Capital Group
  412. Janus Henderson Investors
  413. Jebsen Capital
  414. Jeito Capital
  415. Jiadao Fanghua
  416. Jiadao Private Capital
  417. Jiangsu Huarui Investment Management
  418. Jiangsu Province Hospital of Traditional Chinese Medicine
  419. Jiangyin People's Hospital
  420. Jiaxing Industrial Investment
  421. Jichi Medical University Hospital
  422. Jingjiang People's Hospital
  423. Jingzhou Central Hospital
  424. JM Family
  425. Johnson & Johnson Innovation
  426. Jonsson Comprehensive Cancer Center
  427. Junchenda Capital
  428. Juno Therapeutics
  429. Juventas Cell Therapy
  430. JW Therapeutics
  431. KAEDI
  432. Kaixin Bio
  433. Kangyu Capital
  434. Kangyuan Huiying 
  435. Karolinska Institute
  436. KBI Biopharma
  437. Kecellitics Biotech
  438. Key Biologics
  439. Khosla Ventures
  440. King Star Med
  441. King's College London
  442. Kite Pharma 
  443. Kolon Investment
  444. Korea SMEs & Startups Agency
  445. KSQ Therapeutics
  446. Kuur Therapeutics
  447. Kyverna Therapeutics
  448. Laurion Capital Management
  449. Legend Biotech
  450. Leiden University Medical Center
  451. Leucid Bio
  452. Leukemia & Lymphoma Society
  453. Leukemia Research Foundation
  454. Level One Partners
  455. LG Tech
  456. Life Technologies
  457. LifeSci Venture Partners
  458. Lightchain Capital 
  459. Lightstone Ventures
  460. Lilly Asia Ventures
  461. Liminatus Pharma
  462. Lincoln Park Capital Fund
  463. Lion TCR
  464. Living Pharma
  465. Logos Capital
  466. Longevity Fund
  467. Longitude Capital
  468. Longmen Capital
  469. Longwood Fund
  470. Lonza
  471. Loyal Valley Capital
  472. Loyola University Medical Center
  473. Lucion Group
  474. Ludwig Cancer Research
  475. LUMICKS
  476. LVC Super Unicorn Fund
  477. Lyell Immunopharma
  478. Lytix Biopharma
  479. LYZZ Capital
  480. M.D. Anderson Cancer Center
  481. MabQuest
  482. Malaghan Institute of Medical Research
  483. Malin
  484. Marino Biotechnology
  485. Marker Therapeutics
  486. Massachusetts General Hospital
  487. Massachusetts Institute of Technology
  488. MaSTherCell
  489. Matrix Capital Management
  490. Matrix Partners China
  491. Maverick Ventures
  492. Max Delbrück Center for Molecular Medicine 
  493. MaxCyte
  494. Mayo Clinic
  495. MD Anderson Cancer Center
  496. Medical College of Wisconsin
  497. Medigene
  498. MedImmune
  499. Medisix Therapeutics
  500. MediTrust Health
  501. Medivate Partners
  502. Memorial Sloan Kettering Cancer Center
  503. Merck
  504. Merlin Nexus
  505. Mie University Hospital
  506. Miller Value Partners
  507. Miltenyi Biomedicine
  508. Miltenyi Biotec
  509. Minderoo Foundation
  510. Minerva Biotechnologies
  511. MiNK Therapeutics
  512. Mirae Asset Financial Group
  513. Moderna
  514. MolMed (Acquired by AGC Biologics)
  515. Monashee Investment Management
  516. Moore Strategic Ventures
  517. Morningside Ventures
  518. MSD Partners
  519. Mustang Bio
  520. Myst Therapeutics
  521. Nagoya University
  522. Nanfang Hospital of Southern Medical University
  523. Nanjing Bioheng Biotech
  524. Nanjing Drum Tower Hospital 
  525. Nanjing Children's Hospital
  526. NantKwest
  527. Nantong University
  528. NantWorks
  529. National Cancer Center Hospital East
  530. National Cancer Center Japan
  531. National Cancer Institute
  532. National Education Association
  533. National Heart, Lung and Blood Institute
  534. National Institute of Allergy and Infectious Diseases (NIAID)
  535. National Institutes of Health
  536. National Institutes of Health (NIH)
  537. National Institutes of Health Clinical Center
  538. National Taiwan University Hospital
  539. National University Hospital
  540. Navy General Hospital
  541. Neogene Therapeutics
  542. NeoSTEM
  543. New Enterprise Associates
  544. New Leaf Venture Partners
  545. New York State Stem Cell Science Program (NYSTEM)
  546. Nextech Invest
  547. NIH Small Business Innovation Research (SBIR)
  548. Ningbo Cancer Hospital
  549. Nipro
  550. Nkarta
  551. Noile-Immune Biotech
  552. Northern Jiangsu People's Hospital
  553. Northern Light Venture Capital
  554. Northleaf Capital Partners
  555. Northpond Ventures
  556. Notch Therapeutics
  557. Novartis
  558. Novartis Venture Fund
  559. Novo Nordisk
  560. nSAGE
  561. NSF Engineering Research Center for Cell Manufacturing Technologies
  562. NSR Financial
  563. Nurix Therapeutics
  564. Oaktree Capital Management
  565. Oceanpine Capital
  566. Octagon Capital
  567. OCV Partners
  568. Omega Funds
  569. Oncodesign Biotechnology
  570. Oncora Medical
  571. OncoTracker
  572. Oncternal Therapeutics
  573. OnCyte
  574. ONK Therapeutics
  575. oNKo-innate
  576. Ono Pharmaceutical
  577. Opus Bio
  578. OriginCell Therapeutics
  579. OrbiMed Advisors
  580. ORI Capital
  581. Oriza 
  582. Oriza Seed Venture Capital 
  583. Osage University Partners
  584. Oslo University Hospital
  585. Ospedale Pediatrico Bambino Gesù (OPBG)
  586. Otsuka Pharmaceutical
  587. Ottawa Hospital Research Institute
  588. Outpace Bio
  589. Overland Pharmaceuticals
  590. Oxford BioMedica
  591. Oxford BioTherapeutics
  592. Oxford MEStar
  593. PACT Pharma
  594. Panacea Ventures
  595. PanCELLa
  596. Parker Institute for Cancer Immunotherapy
  597. Partners Innovation Fund
  598. Pediatric Brain Tumor Consortium
  599. Peking Union Medical College Hospital
  600. Peking University People's Hospital
  601. Peking University Shenzhen Hospital
  602. Peking University Third Hospital
  603. Pentwater Capital Management
  604. PeproMene Bio
  605. Perceptive Advisors
  606. Perceptive Bioscience Investments
  607. PersonGen BioTherapeutics
  608. Peter MacCallum Cancer Centre
  609. Pfenex
  610. Pfizer
  611. PFM Health Sciences
  612. PharmaCell
  613. PharmaEssentia
  614. Pharmalog 
  615. Phio Pharmaceuticals
  616. PhoreMost
  617. Pieris Pharmaceuticals
  618. Pierre Fabre
  619. Pinze Lifetechnology
  620. Pitango Venture Capital
  621. Pivotal bioVenture Partners
  622. Plaisance Capital
  623. Platinum Asset Management
  624. Point72
  625. Polaris Partners
  626. PolyBioCept
  627. Pontifax
  628. Posco Capital
  629. Poseida Therapeutics
  630. Precigen
  631. Precision BioSciences
  632. Pregenen (Acquired by bluebird bio)
  633. Presight Capital
  634. Progenitor Cell Therapy
  635. ProMab Biotechnologies
  636. Prometheus Capital
  637. Prometheus Laboratories
  638. Protheragen
  639. Providence Cancer Institute of Oregon
  640. Providence Health & Services
  641. Pura Vida Investments
  642. Qatar Investment Authority (QIA)
  643. QIAGEN
  644. Qian Hai Wan Hui Equity Investment Fund Management (Shenzhen)
  645. Qilu Hospital of Shandong University
  646. Qingzhe Capital
  647. QVT Financial
  648. RA Capital Management
  649. Red Hill Capital
  650. Redmile Group
  651. RedoxTherapeis
  652. Refuge Biotechnologies
  653. Regeneron Pharmaceuticals
  654. Renji Hospital
  655. Resilience
  656. resTORbio
  657. RFund
  658. Ridgeback Capital Investments
  659. Ridgeback Capital Management
  660. RiverVest 
  661. RM Global Partners
  662. Roche
  663. Rock Spring Capital
  664. Rockland Immunochemicals
  665. Roger Williams Medical Center
  666. Rosewell Park Comprehensive Cancer Center
  667. Royal Adelaide Hospital Cancer Centre
  668. RTW Investments
  669. Ruijin Hospital
  670. Ruisheng Investment
  671. Rutgers University
  672. Russian Direct Investment Fund
  673. RXi Pharmaceuticals
  674. Sabby Management
  675. Sabz Biomedicals
  676. Samsara BioCapital
  677. Sana Biotechnology
  678. Sands Capital
  679. Sangamo Therapeutics
  680. Sanofi
  681. Sanofi-Genzyme BioVentures
  682. Schonfeld Strategic Advisors
  683. SciLifeLab
  684. Scotia Biologics
  685. Seattle Children’s Research Institute
  686. Seattle Children's Hospital
  687. Seattle Children's Research Institute
  688. Seattle Genetics
  689. Seattle Cancer Care Alliance
  690. Second Affiliated Hospital of Guangzhou Medical University
  691. Second Affiliated Hospital of Nanchang University
  692. Second Affiliated Hospital of Soochow University
  693. Second Affiliated Hospital of Xi'an Jiaotong University
  694. Second People’s Hospital of Huai’an
  695. Second Military Medical University
  696. Second Xiangya Hospital of Central South University
  697. Sectoral Asset Management
  698. Selexis
  699. Sequoia Capital China
  700. Servier
  701. Shanghai Cancer Institute
  702. Shanghai Biomed-Union Biotechnology
  703. Shanghai Bioray Laboratory
  704. Shanghai Cell Therapy 
  705. Shanghai Changzheng Hospital
  706. Shanghai Chest Hospital
  707. Shanghai Children's Medical Center
  708. Shanghai East Hospital
  709. Shanghai GeneChem
  710. Shanghai General Hospital
  711. Shanghai International Medical Center
  712. Shanghai Jiao Tong University School of Medicine
  713. Shanghai Longyao Biotechnology
  714. Shanghai Ming Ju Biotechnology
  715. Shanghai PerHum Therapeutics
  716. Shanghai Pharmaceuticals
  717. Shanghai Public Health Clinical Center
  718. Shanghai Pudong Science & Technology Investment
  719. Simnova Biotherapeutics
  720. Shanghai Sixth People's Hospital
  721. Shanghai Tongren Hospital
  722. Shanghai Tongji Hospital
  723. Shanghai Ultra-T Immune Therapeutics
  724. Shanghai Unicar-Therapy Bio-medicine Technology
  725. Shanghai Zhongshan Hospital
  726. Shanxi Province Cancer Hospital
  727. Shariati Hospital
  728. Sheba Medical Center
  729. Shenzhen Binde Biotechnology
  730. Shenzhen BinDeBio
  731. Shenzhen Capital Group
  732. Shenzhen Children's Hospital
  733. Shenzhen Geno-immune Medical Institute
  734. Shenzhen Hospital of Southern Medical University
  735. Shenzhen Institute for Innovation and Translational Medicine
  736. Shenzhen Second People's Hospital
  737. Shenzhen University
  738. Sherpa Venture Capital
  739. Shibuya 
  740. ShiJiaZhuang Zhongxi Children Hospital
  741. Shinhan Venture Investment
  742. Shionogi
  743. Shiyu Capital
  744. Shoreline Biosciences
  745. Shougang Fund
  746. Sichuan Kelun-Biotech Biopharmaceutical
  747. Sichuan University
  748. Sidney Kimmel Comprehensive Cancer Center
  749. SignalOne Bio
  750. Sigrid Jusélius Foundation
  751. Simcere Pharmaceutical
  752. Sinobioway Cell Therapy
  753. Sino-Singapore Chongqing Connectivity Private Equity Fund Management
  754. Sirona Capital
  755. Sistema
  756. Sixty Degree Capital
  757. SNU Bio Angel
  758. Sofinnova Partners
  759. Soleus Capital
  760. Sorrento Therapeutics
  761. South China Venture Capital
  762. Southern Medical University
  763. Southwest Hospital
  764. SpringWorks Therapeutics
  765. SR One
  766. St. Baldrick's Foundation
  767. St. Jude Children's Research Hospital
  768. Stage Cell Therapeutics
  769. Stand Up To Cancer
  770. Stanford University
  771. Statcom
  772. Steam Athena Capital
  773. STIC Ventures
  774. Stony Brook University
  775. Stratophase
  776. Structured Immunity
  777. Struengmann Family Office
  778. Summer Capital
  779. Sun Yat-sen University
  780. Surveyor Capital
  781. Suvretta Capital Management
  782. Suzhou Porton Biologics
  783. SV Health Investors
  784. Syncona
  785. Syncopation Life Sciences
  786. Syno Capital
  787. Synthace
  788. Syracuse Biopharma
  789. T. Rowe Price Associates
  790. Tactiva Therapeutics
  791. Taiho Ventures and Wu Capital
  792. Takara Bio
  793. Takeda Pharmaceutical
  794. Takeda Ventures
  795. Tangdu Hospital
  796. TC BioPharm
  797. T-Cell Factory
  798. TCR Biotherapeutics
  799. TCR2 Therapeutics
  800. TCRCure Biopharma
  801. TCRyption (Acquired by Treadwell Therapeutics)
  802. T-Cure Bioscience
  803. T-CURX
  804. Tehran University of Medical Sciences
  805. Tekla Capital Management
  806. Tel Aviv Sourasky Medical Center
  807. Temasek
  808. TeneoBio
  809. Teralys Capital
  810. Terra Magnum Capital Partners
  811. Terumo BCT
  812. Tessa Therapeutics
  813. Texas Children's Hospital
  814. TF Capital
  815. The Affiliated Hospital Of Guizhou Medical University
  816. The Affiliated Hospital of Xuzhou Medical University
  817. The Beijing Pregene Science and Technology
  818. The Children's Mercy Hospital
  819. The Coolsingel Foundation
  820. The Faris Foundation
  821. The First Affiliated Hospital of Anhui Medical University
  822. The First Affiliated Hospital of Dalian Medical University
  823. The First Affiliated Hospital of Guangdong Pharmaceutical University
  824. The First Affiliated Hospital of Guangzhou Medical University
  825. The First Affiliated Hospital of Kunming Medical University 
  826. The First Affiliated Hospital of Nanchang University
  827. The First Affiliated Hospital of Nanjing Medical University
  828. The First Affiliated Hospital of Soochow University
  829. The First Affiliated Hospital of University of Science and Technology of China
  830. The First Affiliated Hospital of Zhejiang University
  831. The First Affiliated Hospital of Zhengzhou University
  832. The First People's Hospital of Hefei
  833. The First People's Hospital of Yuhang District
  834. The First People's Hospital of Yunnan
  835. The Fourth Hospital of Hebei Medical University
  836. The General Hospital of Western Theater Command
  837. The Japanese Society for Regenerative Medicine
  838. The Lind Partners
  839. The Methodist Hospital Research Institute
  840. The Netherlands Cancer Institute
  841. The Ohio State University
  842. The Pregene (ShenZhen) Biotechnology
  843. The Scientific and Technological Research Council of Turkey
  844. The Second Affiliated Hospital of Chongqing Medical University
  845. The Second Affiliated Hospital of Hainan Medical University
  846. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  847. The Second Affiliated Hospital of Anhui Medical University
  848. The Second Hospital of Hebei Medical University
  849. The Second Affiliated Hospital of Nanjing Medical University
  850. The Seventh Affiliated Hospital, Sun Yat-sen University
  851. The Sixth Affiliated Hospital of Wenzhou Medical University
  852. The Third People's Hospital of Kunshan
  853. The Wistar Institute
  854. Thermo Fisher Scientific
  855. Third Rock Ventures
  856. Tianjin Medical University
  857. Tianjin Medical University General Hospital
  858. Tianjin Mycure Medical Technology
  859. Tianjin Venture Capital
  860. TiCARos
  861. TILT Biotherapeutics
  862. Timmune Biotech
  863. Tiziana Life Sciences
  864. T-knife Therapeutics
  865. Tmunity Therapeutics
  866. Tongji Hospital
  867. Tongji University
  868. Torque Therapeutics
  869. Touchstone Innovations
  870. TrakCel
  871. Transgene
  872. Transposagen Biopharmaceuticals
  873. Treadwell Therapeutics
  874. TriArm Therapeutics
  875. Trinity College Dublin
  876. Tri-Service General Hospital
  877. Triumph Over Kid Cancer Foundation
  878. Triumvira Immunologics
  879. Tscan Therapeutics
  880. Tsinghua University
  881. Turnstone Biologics
  882. Twist Bioscience
  883. TxCell
  884. Tybourne Capital Management
  885. Tzitzit Asset
  886. Ucello Therapeutics
  887. UCL Business
  888. UNC Lineberger Comprehensive Cancer Center
  889. Union Stem Cell & Gene Engineering
  890. US Department of Defense
  891. Universal Cells
  892. University College London
  893. University Health Network
  894. University Hospital Basel
  895. Würzburg University Hospital
  896. University Medical Center Utrecht
  897. University of Alberta
  898. University of Birmingham
  899. University of California
  900. University of Chicago
  901. University of Colorado
  902. University of Connecticut
  903. University of Lausanne
  904. University of Milano-Bicocca
  905. University of Minnesota
  906. University of Montreal
  907. University of Munich
  908. University of North Carolina
  909. University of Oxford
  910. University of Pennsylvania
  911. University of South Australia
  912. University of Southern California
  913. University of Texas
  914. University of Tokyo Hospital
  915. University of Virginia Patent Foundation
  916. University of Washington
  917. University of Washington Cancer Consortium
  918. University of Zurich
  919. UNM Rainforest Innovations
  920. Uppsala University
  921. USHEALTH
  922. UTC Investment 
  923. UTC Therapeutics
  924. UWELL Biopharma
  925. V Foundation
  926. VCN Biosciences
  927. Velocity Capital Fintech Ventures
  928. venBio
  929. Versant Ventures
  930. Vertex Pharmaceuticals
  931. VI Ventures
  932. Viking Global Investors
  933. Vineti
  934. Vinnova
  935. ViroMed
  936. Vitruvian Networks
  937. Vivo Capital
  938. Vulpes Investment Management
  939. Washington University
  940. Weill Cornell Medical College
  941. Weill Medical College of Cornell University
  942. Wellington Management
  943. Wellington Zhaotai Therapies
  944. West China Hospital
  945. West China Hospital of Sichuan University
  946. White Rock Capital Management
  947. Woodford Investment Management
  948. Woori Technology Investment
  949. Wugen
  950. Wuhan Bio-Raid Biotechnology
  951. Wuhan Sian Medical Technology
  952. Wuhan Union Hospital
  953. WuXi AppTec
  954. X-Body
  955. Xi'An Yufan Biotechnology
  956. Xiangrong Capital
  957. Xiangxue Life Science Research Center
  958. Xiangxue Pharmaceutical
  959. Xiangya Hospital of Central South University
  960. Xiangyang Central Hospital
  961. Xijing Hospital
  962. Xinhua Hospital
  963. Xinqiao Hospital
  964. Xinqiao Hospital of Chongqing
  965. Xinyi Capital
  966. Xuanwu Hospital
  967. Xuzhou Medical University
  968. Yake Biotechnology
  969. Yamaguchi University
  970. Yan'an Affiliated Hospital of Kunming Medical University
  971. Yeshiva University
  972. Yipu Capital
  973. YuanMing Capital
  974. Yunfeng Capital
  975. Yunnan Cancer Hospital
  976. Zelluna Immunotherapy
  977. Zhejiang Huahai Pharmaceutical
  978. Zhejiang Provincial People's Hospital
  979. Zhejiang Qixin Biotech
  980. Zhejiang University

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com